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ABSTRACT 
Meta-analysis is frequently used in the analysis of safety data. In dealing with rare 
events, the commonly used risk measures, such as the odds ratio, or risk difference, or 
their variance, can become undefined when no events are observed in studies. The use of 
an arcsine transformation and arcsine difference (AD) as treatment effect were shown to 
have desirable statistical properties (Rucker, 2009). However, the interpretation of the 
AD remains challenging and this may hamper its utility. To convert the AD to a risk 
measure similar to the risk difference, two previously proposed linear approximation 
methods, along with new linear and non-linear methods were discussed and evaluated. 
The existing approximation methods generally provide satisfactory approximation when 
the event proportions are between 0.15 and 0.85. We propose a new linear approximation 
method, the modified rationalized arcsine unit (MRAU) which improves the 
approximation when proportions fall outside the range from 0.15 to 0.85. However, the 
MRAU can still lead to under- or over-estimation depending on the underlying 
proportion. We then proposed a non-linear approximation method, based on a Taylor 
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series expansion (TRAUD), which shows the best approximation across the full range of 
risk levels. However, the variance for TRAUD is less easily estimated and requires 
bootstrap estimation. Results from simulation studies confirm these findings under a wide 
array of scenarios.   
In the second section, heterogeneity in meta-analysis is discussed along with 
current methods that address the issue. To provide an exploration of the nature of 
heterogeneity, finite mixture model methods (FMM) were presented, and their 
application in meta-analysis discussed. The estimates derived from the components in 
FMM indicate that even with a pre-specified protocol, the studies included in a meta-
analysis may come from different distributions that can cause heterogeneity. The 
estimated number of components may suggest the existence of multiple sub-populations 
that a simple overall effect estimate will neglect. We propose that in the analysis of safety 
data, the estimates of the number of components and their respective means can provide 
valuable information for better patient care. 
In the final section, the application of the approximation methods and the use of 
FMM are demonstrated in the analysis of two published meta-analysis examples from the 
medical literature.    
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1 INTRODUCTION 
1.1   THE USE OF ARCSINE AND ITS APPROXIMATIONS IN 
META-ANALYSIS OF SAFETY EVENTS 
In human biomedical research, one of most common applications of meta-analysis is the 
analysis of emerging rare safety events with or without certain intervention, such as 
medications or medical procedures. With collection of many studies, meta-analysis 
provides the means to detect statistical associations between event occurrences and the 
intervention that a single study cannot achieve, either because of lack of power due to 
limited sample size, or due to the safety signals not being known ahead of the 
interventions. However, because commonly used risk measures are ratio based and 
heavily rely on asymptotic theory for statistical inference, the occurrence of zero events 
in a single trial can cause an undefined risk measure or variance estimate. Proper 
incorporation of results from these trials poses a challenge in meta-analysis.  For 
example, the highly publicized meta-analysis of association between serious rare 
cardiovascular events and the use of a Type 2 diabetes medicine: Rosiglitazone maleate 
(marketed as Avandia) by Nissan and Wolski (2007 and 2010). The authors employed a 
risk measure that excludes trials with zero events, and concluded the use of rosiglitazone 
associated with significantly elevated risk for myocardial infarction (MI), a condition 
commonly referred to as a heart attack. Diamond and Kaul (2007) examined the impact 
of the exclusion of 4 trials from the MI analysis, and 19 trials from the cardiovascular 
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mortality analysis. Using Bayesian meta-analysis methods with the use of a continuity 
correction that allows values of zero to be included, they found no statistical significant 
risk for either MI or death. However the use of a continuity correction is not without 
concerns (Grizzle, 1967; Sweeting et al., 2004).  As a possible remedy, an arcsine 
transformation based measure, the arcsine difference (AD), can accommodate zero events 
in a natural way. As shown in Rucker et al. (2009), the AD is always defined, with its 
variance determined by sample size only and thus not affected by zero events.  
 
Relating the AD to actual treatment differences, however, is not obvious and because of 
this, the application of AD has been limited. Transforming AD into a more intuitive 
measure may improve its utility. In my research, two existing linear approximations of 
arcsine transformation: rationalized arcsine unit (RAU, Studebaker, 1985), and Stevens 
arcsine unit (SAU, Stevens, 1953) are reviewed. The difference in these units between 
treatment and control (RAUD and SAUD) were computed as risk measures. While both 
linear approximations converted the AD to a percentage-like risk difference measure, 
there was considerable bias when event proportions were close to 0 or 1. Therefore, as an 
improvement, I proposed a modified version of the RAU (called MRAU) that maintains 
the linear approximation of the RAU with refined accuracy when the event proportions 
fall outside of 0.15 and 0.85, and a risk difference measure: MRAUD. Further, a new 
non-linear approximation method based on Taylor’s theorem (TRAU) is proposed to 
closely convert the arcsine transformation to a percentage regardless of the underlying 
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event proportions. The risk difference measure based on this method is denoted as 
TRAUD. 
 
Simulation studies were conducted to evaluate the performance of these approximation 
methods under various meta-analytic scenarios. The simulated studies (trials) included 
two parallel treatment groups (i.e. treatment vs. control), various event proportions in the 
two groups, and different treatment allocation ratios. These scenarios were selected to 
closely resemble a wide array of published meta-analyses from medical journals. Relative 
bias and coverage probabilities were calculated, and comparisons among the four 
methods are provided.  
 
Finally, the four approximation methods were implemented in the re-analysis of 
association between cardiovascular events and rosiglitazone treatment, using data 
obtained from Nissen and Wolski (2010). Using inverse variance meta-analysis methods, 
the overall risk of MI and cardiovascular mortality are derived and discussed.  
 
1.2 THE USE OF FINITE MIXTURE MODEL TO ADDRESS 
HETEROGENEITY IN META-ANALYSIS 
The primary objective in meta-analysis is to obtain an overall estimate of effect across the 
collection of primary studies, such as odds ratio for a risk factor, or mean difference 
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between treatments. This overall estimate provides a single point estimate for the 
scientific hypotheses under investigation. This can be achieved using a fixed effect model 
if the homogeneity assumption holds for the studies. When one believes that studies 
including a meta-analysis have enough in common that it makes sense to synthesize the 
data across the studies, but there is generally no basis to assume that they are identical 
with exactly the same true effect (heterogeneity), a random effects model may be used to 
obtain an overall measure. 
 
It has been argued that generalizability of meta-analysis results might be explored 
through additional analyses that incorporate specific predictive uncertainties on top of the 
intrinsic uncertainties of the studies under review (Ades and Higgins, 2005). It is possible 
that even with a carefully pre-specified protocol, the studies included in a meta-analysis 
may come from more than one sub-population.  In such a situation, the use of a single 
overall measure may not be appropriate, or may be misleading to our understanding of 
the true nature of the treatment under investigation.  Recent development in Finite 
Mixture Model (FMM) methodologies shows some desirable capabilities for potentially 
exploring heterogeneity in many settings, including meta-analysis. FMM provides a 
natural representation of heterogeneity by assigning outcomes to a finite number of latent 
groups. Therefore it essentially assumes that the data come from different sub-
populations in terms of the response of interest. This is particularly appealing in meta-
analysis settings as studies are often conducted at different times, at different 
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geographical locations, or with different patient populations. These and other observable 
and unobservable factors are all potential sources of heterogeneity and covariate 
adjustments are sometimes impossible due to the lack of subject-level data in study 
reports. The FMM provides a framework for estimating the number of mixture 
components, therefore identifying homogeneous clusters of studies. This may provide 
insight into the underlying factors that influence intervention effects that random effect 
models do not address.  
  
1.3 STRUCTURE OF THE DISSERTATION 
This first part of the dissertation develops novel approximation methods of arcsine 
transformation for utility in meta-analysis of binary data. In Chapter 2, after introducing 
the two existing linear approximation methods (RAU and SAU), a modified linear 
approximation method (MRAU), and a new non-linear approximation method (TRAU) 
are proposed. Risk measures are then developed by using the unit differences between 
treatment and control groups. The performances of these methods are evaluated through 
extensive simulation studies, followed by discussion and conclusions. The second part of 
the dissertation focuses on addressing meta-analysis heterogeneity with finite mixture 
model methodologies.  In Chapter 3, following brief descriptions of the fixed effect and 
random effects models, FMM theory is introduced, including current methods of 
identifying the number of components, component parameter estimation, and Bayesian 
6 
 
 
 
hierarchical model methods. Applications to meta-analysis are discussed in detail. In 
Chapter 4, two safety data meta-analysis examples are provided, with datasets from 
recent publications. The approximation methods are then applied to the rosiglitazone 
dataset in the evaluation of rosiglitazone treatment and the occurrence of cardiovascular 
diseases. The risks of MI and cardiovascular mortality are obtained and inference is 
made.  Then, the FMM methods in meta-analysis are applied to a Behcet’s disease dataset 
known to be heterogeneous. The association between HLA-B51/B5 carriage and BD 
development is investigated. Results from FMM analysis are compared to those obtained 
from both fixed effect and random effects models, followed by discussion and 
conclusions. 
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2 EVALUATION OF APPROXIMATIONS OF ARCSINE 
TRANSFORMATION IN META-ANALYSIS OF STUDIES WITH 
BINARY OUTCOMES 
SUMMARY 
 
The arcsine transformation has long been used as a variance stabilization method for 
analysis of binary data. The arcsine differences (AD) has recently been proposed as an 
effect measure in the meta-analysis of safety data, in particular when events are sparse. 
However, due to the lack of intuitive interpretation, the utilization of AD has been 
limited. Two linear approximation methods were found in the literature for converting the 
AD to a percentage-like quantity, such that an approximation of the AD is similar to a 
risk difference (RD). Both approximations performed poorly when evaluated in various 
simulation settings focused on sparse data in terms of relative bias, and 95% coverage 
probability. A modified linear approximation method (MRAUD) was proposed with an 
improved fit when proportions are close to 0 or 1. Although the performance of MRAUD 
was better than the two existing methods under most simulation scenarios we considered, 
the relative bias can still be high when the event proportion is low, and its coverage 
probability was under the nominal level for almost all situations. A non-linear 
approximation of the AD (TRAUD) was derived using the Taylor series expansion and 
was evaluated in comparison to the three linear approximation methods. TRAUD showed 
superior performance in both relative bias and 95% coverage probability. Except for 
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when both the event probability and relative risk are very low (e.g. 0.01, RR = 1.5), the 
coverage probability reached the nominal level under almost all conditions. Therefore 
TRAUD can be used as a tool to solve the lack of interpretability of the AD, and may 
lead to broader utility of AD in meta-analysis of binary data with sparse events. 
 
2.1 INTRODUCTION 
Binary outcomes are common in human medical research studies, where the outcome is 
either occurrence of an event, or the non- occurrence of the event (i.e. presence or 
absence).  For instance, whether or not a disease is cured, whether a patient reaches a pre-
defined clinical threshold after treatment intervention, or whether a patient survived or 
died after cancer surgery. This type of endpoint is intuitive for interpretation and 
understanding by clinical researchers. For example, in epileptic intervention studies, a 
responder to the intervention is defined as a reduction of seizure counts by at least 50% 
during a fixed time interval compared to a pre-treatment period. This would be 
considered an indicator of a clinically meaningful positive treatment response. Because of 
the simple and readily understood nature of this outcome, this is a commonly reported 
endpoint in anti-epileptic studies to show whether a particular anti-epileptic drug is 
efficacious. In smoking status studies, the common binary outcome is smoking cession or 
lack of cessation following an intervention.  
9 
 
 
 
At the end of a standard randomized clinical trial with two treatment groups, the binary 
outcome data is typically presented with a 2 x 2 contingency table:   
 Events Non-events  
Treated A B nt 
Control C D nc 
Table 2-1 Binary outcomes by treatment 
 
A and B represent the event and non-event counts (also called cell counts) from the 
treatment group with sample size of nt subjects.  Likewise, C and D are cell counts for the 
control group of size nc. A/nt is the proportion of events in the treated group (pt); 
likewise, C/nc is the proportion of events from the control group (pc).  For example, in a 
hypothetical drug study, 5 (A) study subjects had serious adverse events during the study 
period in the treatment group of size 120 (nt) representing a 0.042 event proportion, if 3 
(C) subjects from control group of size 120 (nc) show a response, then there would be a 
0.025 event proportion for controls. In medical research studies, most safety outcomes 
are binary outcomes, sometimes including the evaluations of continuous measurement 
(e.g. laboratory measurements of blood chemistry and hematology parameters). 
Dichotomization of a value based on certain threshold is common, such as whether a test 
is considered as clinically significant. 
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In a meta-analysis of studies with binary outcomes, cell counts from the 2 x 2 table from 
each study are used as input data to examine heterogeneity, and are combined to obtain 
an overall measure when appropriate. In a meta-analysis of rosiglitazone treatment of 
persons with type 2 diabetes mellitus trials, Nissen and Wolski (2007) selected 42 
randomized trials with study durations of more than 24 weeks, and control groups not 
receiving rosiglitazone. In each trial, the number of cases of myocardial infarction, and 
death from cardiovascular causes were obtained for the rosiglitazone and control groups. 
Statistical heterogeneity across the trials was tested with the use of Cochran’s Q statistic, 
and the Peto method was used to obtain an overall measure of risk for rosiglitazone 
treatment. 
 
2.2 REVIEW OF COMMONLY USED RISK MEASURES IN 
STUDIES OF BINARY OUTCOMES  
For binary outcome data, there are several measures used to provide an effect estimate for 
the treated group compared to the control, both in relative and absolute terms. The 
following sections describe commonly used risk measures and their statistical properties. 
2.2.1 Relative Risk 
 
The relative risk (RR) is defined as the ratio of risks from treatment ( tp ) and from 
control ( cp ). It is also called Risk Ratio, defined as 
11 
 
 
 
RR=
c
t
p
p . 
It is estimated by 
∧
RR =
c
t
c
t
nC
nA
p
p
/
/
ˆ
ˆ = ; where ,/ˆ tt nAp =  and cc nCp /ˆ = . 
 
Lachin (2000) discussed the RR measure extensively. The domain for RR is (0, ∞), 
where a RR of 1 indicates that the risk is the same in the two groups. Because the domain 
is not symmetric, 
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Further, as the sample sizes nt and nc tend toward infinity, 
Ln(
∧
RR ) ~ N(Ln(RR), V[Ln(
∧
RR )]). 
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The Ln(RR) along with confidence intervals are typically converted back to RR by 
exponentiation in reporting the relative risk results for two groups.  The contour plots of 
RR and Ln(RR) for two proportions are displayed graphically in Figure 2-1. As shown, 
the RR is centered at 1, and 0 for Ln(RR),  in situation when the risks in both groups are 
equal. However, the magnitude of RR can change dramatically when the risk in the 
treatment group is high, relative to risk in the control group. In contrast, the Ln(RR) 
changes rapidly when the risk is low in either group.  
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Figure 2-1 Contour plots of RR and Ln(RR) over the [0, 1] for two proportions. 
Horizontal axis represents the risk in the treatment group, and the vertical axis indicates 
risk in the control group.  
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The RR is commonly used in both cross-sectional and prospective studies. For example, 
Levcht et al (2009) used the relative risk as a measure showing all second-generation 
antipsychotic drugs were associated with much fewer extrapyramidal side effects than 
haloperidol in a meta-analysis. 
2.2.2 Odds Ratio 
 
Another common measure, Odds Ratio (OR) is the ratio of odds of an event on treatment 
and the odds of an event on controls, defined as 
OR= 
)1/(
)1/(
cc
tt
pp
pp
−
−
 
The OR is estimated by  
=−
−=∧
)ˆ1/(ˆ
)ˆ1/(ˆ
cc
tt
pp
ppOR
BC
AD
. 
An OR of 1 indicates that the condition or event under study is equally likely to occur in 
both groups. An OR greater than 1 indicates that the condition or event is more likely to 
occur in the treatment group, and an OR less than 1 indicates that the condition or event 
is less likely to occur in the treatment group. The OR is nonnegative, but it is undefined if 
the denominator BC equals zero, i.e., if either pc is equal to zero or pt is equal to one. 
Similar to the RR, the natural logarithm transformation of the OR is used in statistical 
inference. In large samples, the ln(
∧
OR) is approximately normally distributed with an 
asymptotic variance of 1/A + 1/B + 1/C + 1/D.  
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The OR and Ln(OR) for two proportions are displayed graphically in Figure 2-2. When 
the odds of an event in the treated group are high, and low in the control group, the OR 
increases rapidly, with maximum of infinity, while in the reverse situations, the OR 
approaches zero as minimum. 
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Figure 2-2 Contour plots of OR and log (OR) for two proportions [0, 1]. 
Horizontal axis represents Pt, vertical axis represents Pc 
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different. As was the case for the RR, the OR is an appropriate measure for cross-
sectional or prospective studies. In addition, the OR may also be used for retrospective 
studies such as case -control studies in which RR is not an appropriate risk measure. For 
example, Kolahdooz et al. (2010) used data from 2 Australian population-based case-
control studies (2049 cases and 2191 controls). Their meta-analysis of retrospective case-
control studies showed that women with the highest intake of processed meat had a 
significantly increased risk of ovarian cancer. The combined OR was 1.18, with 95% 
confidence interval (CI) from 1.15 to 1.21. The OR is frequently used in biomedical 
research, and is therefore a common measure used in meta-analysis. Two specific 
methodologies were developed for combining ORs: the Peto method (1985) and the 
Mantel and Haenszel method (1959).  
2.2.3 Risk Difference 
 
The risk difference (RD) is the simple algebraic difference between the risks of having an 
event on the treatment and the control, defined as 
RD= ct pp − , and estimated by 
ct ppRD ˆˆ −=
∧
=A/nt – C/nc 
The domain of the RD is [-1, 1] with a null value of 0. The inverse of the RD is called the 
number needed to treat (NNT), which is an important measure in clinical epidemiology. 
If a clinical endpoint is devastating enough (e.g. death, heart attack), drugs with a small 
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RD may still be indicated in particular situations. The asymptotic distribution follows 
directly from that of the sample proportions themselves since the RD is a simple 
difference of two independent proportions, each of which is asymptotically normally 
distributed. Thus 
]
)1()1(
,[~ˆˆ
c
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tt
ctct n
pp
n
pp
ppNpp
−+−−− . 
Figure 2-3 shows the risk measures for event probability range between 0.15 and 0.95 in 
the treatment group with a constant RD of 0.1, along with corresponding RR and OR. A 
constant RD corresponds to different measures of RR and OR depending on the region of 
the risks in bother the treated and control groups. For example, when the event risk in the 
treatment group is 0.95, with a RD of 0.1, the corresponding RR is 1.11, while the OR is 
3.35. It is not shown in the figure, that when the risk in the control group is near zero, 
both the RR and OR approach infinity. In comparison, when the risk is near 1 in the 
treatment group, only the OR approaches infinity, the RR converges to 10/9.   
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Figure 2-3 Relationship among a constant RD of 0.1, and corresponding RR and OR for 
risk range from 0.15 to 0.95 in the treatment group.   
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(Levenson, 2008), the main statistical analysis involved separate examination of the 
increased risk for suicidality for each randomized clinical trial. These were then 
combined to yield one summary measure of the increased risk for suicidality across all 
anti-epileptic drugs and indications, using the exact method (Cytel, 2005). Unfortunately 
this method eliminates trials with no suicidality events in either arm, considering them 
uninformative. According to the FDA report, this represented 133 of the 199 trials 
(66.8%), leaving only 66 trials for the main analysis (Hesdorffer et al. 2009). As a 
remedy to this situation, a ‘continuity correction’ is used frequently. As a standard 
practice, a small constant, usually 0.5, is added to each of the cell counts, and the analysis 
is carried out using the new numbers in each cell within each study. These study 
estimates are then used as input data in meta-analysis.  In the following section, I will 
discuss the use of continuity correction and its pros and cons.  
2.2.4 Accounting for data with sparse outcomes 
 
As discussed in previous sections, commonly used measures become less stable when 
cell counts in 2 x 2 tables are small, and measures can even become un-evaluable when 
certain cell counts are zero. Several methods to address this situation have been proposed 
in literature. 
 
Yates (1934) introduced the continuity correction in the context of application of the χ2 
tests to 2 x 2 contingency tables when cell counts were small. Since the square root of χ2 
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is distributed normally for one degree of freedom, the exact probability corresponding to 
this value of χ2 can be obtained by taking the square root and using a table of the normal 
probability integral. However, the χ2 from 2 x 2 contingency table always under-estimates 
the exact probability (i.e. binomial probability). This is primarily due to the fact that χ2 is 
a continuous distribution, used to approximate a discrete distribution. Yates grouped the 
χ2 distribution, taking the half units of deviation from expectations for the group 
boundaries. The grouped approximation provided probabilities much closer to the true 
distribution. This is equivalent to computing the values of χ2 for deviations half a unit less 
than the true deviations.  This correction is called correction for continuity. The 
probability obtained with the continuity correction is closer to the true probability, though 
it over-estimates at the tail areas, and under-estimates near the center of the distribution.   
 
Plankett (1964) approximated to the distributions of both the uncorrected and corrected 
standard test criteria for 2 x 2 tables when independent samples were taken from 
binominal populations with the same parameter. The results were applied to study the 
overall performance of χ2 corrected for continuity, and confirmed that a correction was 
inappropriate if the reference set considered relevant was generated by independent 
binomial samples. Grizzle (1967) also pointed out that the correction caused type I error 
increase even in small sample situations. 
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However, the continuity correction became widely used. Mantel and Greenhouse (1968) 
disputed Grizzle’s findings, and concluded “it is simply a device for evaluating 
probabilities when a discrete distribution is being approximated by a continuous one.” 
Cox (1970) provided an elementary analytical derivation, showing that, if a discrete 
distribution is approximated by a continuous distribution with the same mean, then c=0.5 
makes the average error of approximation equal to zero. 
  
Other alternative correction methods have also been proposed. Sweeting et al. (2004) 
proposed two additional possible continuity correction methods. One method is called 
‘The reciprocal of the opposite treatment arm size.’ This calls for adding k/nc to treatment 
group cells, and k/nt to the control group cells, where k is a proportionality constant. It 
was stated that this adjustment may cause less bias when the size of the treatment groups 
is severely unbalanced. The other method is called ‘An empirical continuity correction.’ 
This method was proposed in the context of meta-analysis where only a subset of the 
studies needed continuity correction adjustment. A correction factor is empirically 
derived from the non-zero event studies in such a way that it ‘pulls’ the estimate in the 
direction of the pooled effect size estimate obtained in the analysis after applying the 
factor to both arms.  The authors further investigated the performance of 5 commonly 
used meta-analysis methods with continuity correction when the studies have sparse 
event data. Various scenarios were considered in simulation settings including that of 
severe treatment imbalance. They found that the performance varied with the choice of 
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continuity correction methods. The two alternative methods outperformed the commonly 
used constant correction factor in nearly all situations. However, the validity of the two 
alternative methods remains to be demonstrated under wider conditions. In particular, for 
the computational complexity of the empirical continuity correction method precludes 
broad use.  These prior studies highlight the need for a measure that can perform under 
various sparse data situations and is easily obtainable.  
  
2.3 REVIEW OF ARCSINE OR ANGULAR TRANSFORMATION 
 
The inverse of sine (or arcsine) square root transformation is 
f(x) = Sin-1 nx / , or 
f(x) = arcsine p   
where x is the number of events from n Bernoulli trials, and p= x/n. This transformation 
was given in Fisher and Yates’s statistical tables in 1938. It has been used with particular 
reference to Analysis of Variance (ANOVA) where non-normally distributed data are 
transformed to obtain normality and stable variance. However, the interpretation of the 
arcsine transformation provides a barrier to its widespread employment.  
 
A graphical interpretation of the transformation was elegantly demonstrated by Rucker et 
al. (2009), which is depicted in Figure 2-4. 
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Figure 2-4 Graphical interpretation of arcsine transformation (length of arc in blue), 
square root transformation (length of the dashed line) of a proportion (p, length of the red 
line).  
 
The arcsine p  corresponds to the length of arc on a semi-circle above the line segment 
from 0 to p. This is symmetrical around 0.5 (or 50%) in that it is also equal to the length 
of arc above 1-p to 1. The transformation is equal to 0, π/4 and π/2, for p = 0, 0.5, and 1, 
respectively. Figure 2-5 shows the arcsine transformation values for p from 0 to 1. 
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Figure 2-5 Arcsine p value vs. p for proportion from 0 to 1 
   
Bartlett (1947) discussed the use of the arcsine transformation as one of four commonly 
used transformations. The main advantage of the arcsine transformation is that the 
variance of the transformed value is solely determined by the sample size n.  The 
approximate variance of the transformation is 821/n, if measured in degrees, and is 1/4n, 
if measured in radians.  
 
Sprott (1973) examined the relationship between transforming likelihoods to normality 
and the resulting accuracy of the confidence intervals and significance levels obtained 
from large sample theory applied to the transformed parameters. A measure of deviation 
from normality was derived from the Taylor series expansion of the log likelihood as 
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where R(θ; X) is the relative likelihood function of θ based on the density function of the 
observations (f(X; θ), is defined as R(θ; X) = f(X; θ)/supθf(X; θ), and Iθ is the Fisher 
observed information. 
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The smaller the deviation |FE(θ)| from normal likelihood the closer the transformation is 
to normality. Compared to the logit transformation of γ=log{(1-θ)/θ}, the arcsine 
transformation (ψ= arcsine p ) had only half the deviation from normality 
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1)( θψ FF = ), when θ has a binomial distribution. 
 
Freeman and Tukey (1950) further proposed the average angular transformation for 
variance stabilization with small counts. The Freeman-Tukey transformation is 
f(x) = sin-1
1+n
x  + sin-1
1
1
+
+
n
x . 
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This transformation was derived from empirical study, with variance within ±6% of  
2/1
1
+n  if angles were measured in radians, or 2/1
821
+n  if angles measured in degrees, 
for almost all cases where np ≥ 1.  
 
Mosteller and Youtz (1961) examined properties of Freeman and Tukey’s arcsine 
transformation. For n=1 to 50, and x=0 to n, the relationship between the maximum 
variance ( 2θσ ) and asymptotic variance ( 2 ∞−θσ ) was tabled and presented graphically. The 
asymptotic variance ( 2 ∞−θσ ) is higher than the maximum variance ( 2θσ ) when p is near 
zero or close to 1, with the difference more pronounced when sample size is small 
(n<10).  
 
D’Agostino (1971) also discussed the use of arcsine transformation in the context of 
analysis of variance on dichotomous data. The transformation can be used as a means to 
stabilize the variance regardless of p, which allows simpler analysis, such reducing the 
weighted ANOVA to an un-weighted analysis. 
 
Chen (1990) considered the uniform convergence of the coverage probabilities of some 
approximate confidence intervals for binomial parameter p, induced by central limit 
arguments. The coverage probability of the interval induced by the arcsine transformation 
is shown to be very close to the upper bound, suggesting that the arcsine is almost the 
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optimal transformation. Replacing x/n by the Bayes estimate (x + β)/(n + 2β) for some β 
provided even better uniform asymptotic properties. The author recommended  
β = 2/2αZ , where αZ is the (1 - α)th quartile of the standard normal distribution. 
 
Rucker et al. (2008) introduced the use of a test based on the difference in arcsine values 
for publication bias in meta-analysis with binary outcomes. Publication bias, also called 
the “small study effect,” refers to the situation where smaller trials show different, often 
greater, treatment effects than larger studies.  Several tests for small study effects had 
previously been developed. Rucker et al. grouped these into two broad classes: (i) non-
parametric tests using rank-correlation methods; and (ii) regression tests. The null 
hypothesis for these tests included in a meta-analysis, is that there is no association 
between effect size and precision. The lack of association is violated by the common 
measures for binary outcomes (RR, OR, and RD). Because the arcsine transformation 
stabilizes the variance, and most importantly, removes the association between the 
measure of effect (difference in arcsine) and its variance, Rucker et al. proposed using 
this measure as a basis for testing for publication bias with binary outcomes. Results from 
simulation studies showed the test had comparable size to those of the best existing tests, 
with slightly greater power. 
 
Rucker et al. (2009) followed up with an extensive discussion of the use arcsine 
difference (AD) as a measure of treatment effect in meta-analysis. The graphical 
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interpretation of the AD and its correspondence to a risk difference is provided in Figure 
2-6. 
 
Figure 2-6 Graphic interpretation of arcsine differences (length of arc in blue line) for a 
fixed risk difference (length of the red line).  
 
The arcsine difference (Sin-1 tp  - Sin
-1
cp ) is the difference between the two arc 
lengths. It ranges from - π/2 (when pt = 0, pc = 1) to π/2 (when pt = 1, pt = 0), and is 
symmetrical around 0 (see Figure 2-7).  
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Figure 2-7 Contour plot of arcsine difference between Pt and Pc for two proportions 
 
A 3-D surface plot of relationship among the AD and proportions in the treatment and 
control groups are displayed in Figure 2-8.  
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Figure 2-8 3-D plot of the arcsine difference for all regions of Pt and Pc. 
 
Unlike several other commonly used measures for binary outcomes, the AD effect 
estimate is always defined, and its asymptotic variance is always finite and non-zero. It is 
particularly useful in studies with zero cells, such as situations where rare events are of 
interest. This is particularly important in meta-analysis for assessing risk associated with 
rare safety events, which is a common utilization of meta-analysis. As noted in Rucker et 
al. (2009), the asymptotic variance of the arcsine transformation is always finite, but it 
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under-estimates the true variability when p is near to zero. To account for lack of 
accuracy of the variance estimate, the authors derived a new analytical calculation of the 
variance. They showed that instead of 1/4n as shown previously, the variance is better 
approximated by 0.42/n for large n when the event probabilities are less than 0.2 or above 
0.8. Simulation results were obtained from scenarios with OR from 0.75 to 2 with event 
proportion in control group within 0.05, and 0.50 to 0.80 subjects assigned to treatment 
group. AD with both analytical and conservative variance calculations were compared to 
OR (MH) with and without zero trials, Peto method in terms of bias of treatment effect 
estimate and coverage of 95% confidence interval. They found the variance estimate of 
the AD to be more stable than that of the log OR, even if events were rare. However, 
parameter estimation can be biased if the groups are markedly unbalanced and the events 
are rare in both groups.  It was argued that the use of AD in meta-analysis warrants 
consideration due to its theoretical advantages.   
 
In spite of the desirable statistical properties of the arcsine transformation, and its 
implementation in R packages such as meta (Schwartzer 2007), its interpretation remains 
difficult for broader audiences. The lack of intuition in terms of measuring risk using AD 
may limit its use (Rucker, 2008). For example, in a systematic review of benefits and 
harms of in-hospital use of Recombinant Factor VIIa for off-label indications, the authors 
calculated the effect-size both in RD and arcsine differences. For ease of interpretation, 
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the AD results were not reported, justified by outcome proportions similar across studies 
such that disadvantages of the RD metric were minimized (Yank 2011).   
In the following sections of this chapter, I will explore potential methods for 
approximation for the arcsine transformation so that it may be presented in a more 
intuitive manner yet maintain its statistical advantages.      
 
2.4 LINEAR APPROXIMATION OF ARCSINE 
TRANSFORMATION 
 
If a transformation can be established that (a) is linear and additive; (b) produces 
inferential statistical results equivalent to those based on arcsine transformed data; and (c) 
produce values with mean and variance that can be interpreted like percentages, this 
would allow wider implementation of arcsine-based methods.  
2.4.1 Existing approximations 
 
Searching through the literature, two transformations of the arcsine were located. These 
approaches, due to Stevens and Studebaker, are presented in the next two sections. 
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2.4.1.1 Stevens Arcsine Unit (SAU) 
 
 
An early attempt by Stevens (1953) was to find a linear transformation of  the arcsine 
transformation so that it provided similar accuracy to that of the probit transformation. 
His transformation (noted as SAU hereafter) was defined as 
SAU = 50 – 1000 Sin-1(1 – 2p), where p ≤ 0.5. 
The equation produces SAU values between 0 and 50. The values above 50 are derived 
by subtracting from 100%, such as SAU equals to 50 + 1000 Sin-1(1 – 2(1-p)).  
Therefore the SAU is a percentage like quantity. It ranges from 0.327 to 99.673, and has 
almost the maximum possible accuracy for any given arcsine transformed proportion.  As 
can be seen in Figure 2-9 the differences between proportion (in %) and the SAU are near 
zero at 0%, 50%, and 100%.  However, the difference changes drastically when 
percentages are between these values. For example, the SAU values are 6.66%, 9.30%, 
and 11.34% for proportions of 1%, 2%, and 3%, respectively. 
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Figure 2-9 SAU values vs. Proportion (P) from 0 to 1 (upper panel), and difference (in %) 
between SAU and proportion P (lower panel).  
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2.4.1.2 Rationalized Arcsine Unit (RAU) 
 
In 1985, Studebaker proposed a “rationalized” arcsine transformation for use in area of 
speech and hearing research where results are often expressed as proportions or 
percentages.  The goal of the transformation was to produce values very close to 
percentages over a broad region extending outward in each direction from 50%. Two 
multipliers were used.  First, each arcsine value is multiplied by a number that makes the 
rationalized arcsine transformation of the proportion 0.50 have a value of 50, such that 
50% would always have a transformed value of 50 rationalized arcsine units (RAU). The 
second multiplier was chosen so as to produce a scale in which the transformed and the 
un-transformed values differed by less than 1.0 over as broad a region as possible 
centered at 0.5. This multiplier was calculated empirically to be 1.46. The following 
equation describes the RAU transformation  
RAU=1.46(31.83098861*2* Sin-1 nx /  -50)+50, or  
RAU=1.46(31.83098861*2* Sin-1 pˆ -50)+50.  
Along with the SAU approximation, the RAU values are shown plotted against 
proportion in Figure 2-10. 
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Figure 2-10 RAU and SAU values over 0 to 1 proportion P (upper panel), and difference 
(in %) between RAU/SAU vs. proportion P (lower panel).  
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values of P between 0.15 and 0.85. Outside this range from 0.15 to 0.85, the differences 
increase and reach 23% at 0 and 1 (or 100%). Compared to SAU, the RAU provides 
closer approximation for all P in the mid-range, except for P of 0.5, where they both are 
forced to be 50%. 
 
The RAU transformation has been used frequently in fields related to speech and hearing. 
For example, in research to determine the efficacy of “simultaneous” bilateral cochlear 
implantation during a single surgical procedure, Litocsky et al. (2009) transformed 
speech understanding in quiet individual test scores (proportion of correct questions over 
all questions) into RAUs and performed parametric statistical analysis of the RAUs. 
Another example, a study by Bradlow and Bent (2008), investigated talker-dependent and 
talker-independent perceptual adaptation to foreign-accent English. An intelligibility 
score for each speaker based on results from sentence-in-noise recognition tests with 
native English listeners was converted to RAU, and various analyses were then carried 
out.  They found that there was no difference in intelligibility for the Chinese-high talker 
across the single- and multiple-talker tests, probably due to a ceiling effect at 93 RAU 
keywords correctly recognized. There was minimal improvement from the multiple- (70 
RAUs) to the single-talker (71 RAUs) presentation format from the Slovakian-medium 
talker. 
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Although both transforms are intended to produce transformed scores that are more 
percentage-like than the arcsine transformation and work well to use in inferential 
statistical procedures, they both deviate significantly from the underlying proportion in a 
certain range. When the proportions are small, such as <0.15, the RAU under-estimates 
while the SAU over-estimates the true proportion. This is an important limitation for their 
potential utilities in meta-analysis of safety data where often the risks of serious safety 
events are within that range. The discrepancy due to the approximation can, in rare event 
situations, be multiple times of the magnitude of the actual risk. Such discrepancies can 
mask the true risk due to an intervention, and ultimately lead to erroneous conclusions. 
 
2.4.2 Proposed improvement - Modified Rationalized Arcsine Unit 
(MRAU) 
 
Studebaker (1985) argued that the RAU is a better choice than the SAU for most 
purposes because it produces transformed results that differ by relatively small and nearly 
constant amounts for a broad range of untransformed proportions (or scores). Also for the 
purposes of analyzing safety event data, the event proportions are usually very low. 
Therefore, I explored potential improvements to the RAU transformation. As discussed 
earlier, the RAU is centered at 50%, and the approximation gets worse for proportions 
further outside the mid-range. To correct that, I fit two separate linear regression lines for 
proportions 0.15 or lower and 0.85 and above.  Least squares estimates of the linear 
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coefficients were obtained; MRAU is proposed as such to cover the full range of 
proportion: 
P ≤ 0.15, MRAU=39.30+43.82* Sin-1 p ; 
P > 0.15 but < 0.85, MRAU=RAU; 
P ≥ 0.85, MRAU= 54.63+31.43* Sin-1 p ; 
The maximum deviation from the underline proportion is within 4% for the entire range 
of P, as shown in Figure 2-11.   
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Figure 2-11 RAU, SAU, and MRAU values over proportion (P) 0 to 1 range (upper 
panel), and difference (in %) between RAU, SAU, MRAU vs. P (lower panel).  
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Because these transformations are linear, the asymptotic variances for each 
transformation can be easily obtained from the asymptotic variance of arcsine pˆ , and 
the computation is simple to implement (Table 2-2). 
 
Table 2-2 Variance estimates for linear approximations of arcsine transformation 
Approximation  Variance estimate 
arcsine pˆ  
RAU 
 
SAU 
MRAU 
n4
1
 for 0.2 < p < 0.8, or 
n
42.0
 for 0.80 ≤ p ≤ 0.20 
(2*146/3.1416)2*var(arcsine pˆ ) 
n
1000
 
43.822* var(arcsine pˆ ) for p ≤ 0.15 
Var(RAU) for 0.15 < p < 0.85 
31.432* var(arcsine pˆ ) for p ≥ 0.85 
 
 
2.5 PROPOSED NON-LINEAR APPROXIMATION METHOD 
 
Although the linear approximations discussed in the previous section perform reasonably 
well, for low event proportions, the approximation can be improved by adding non-linear 
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terms. The Taylor’s theorem was used to obtain a new rationalized arcsine unit (TRAU).  
The Taylor’s series expansion is defined as: 
...
!3
)()(
!2
)()(
!1
)()()()(
3
'''
2
''' +−+−+−+= axafaxafaxafafxf  
where f(x) = sin(x), x= sin-1 p , and a=0. The Taylor series for sin(x) around the 
neighborhood of 0 is approximately 
sin(x)  ≈ [ )(
50401206
9
753
xOxxxx +−+− ]2, 
By examining the approximation about x (or sin-1 p ) = 0, it was clear that up to order 5 
can perform adequately, therefore the following is used for TRAU. 
TRAU = 100*[ 2
5131
1 ]
120
)(
6
)( pSinpSin
pSin
−−
− +−  
The TRAU generates a value between 0 and 100 for p < 0.994. The maximum bias 
(TRAU – P) reaches 0.9% when p = 1. The approximation is shown graphically in Figure 
2-12 for all p in its domain.  
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Figure 2-12 RAU, SAU, MRAU, and TRAU values over proportion (P) 0 to 1 (upper 
panel), and difference (in %) between four approximation methods vs. proportion P 
(lower panel).  
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In the rare event region (p ≤ 0.15), the non-linear method (TRAU) approximates the best 
compared to all three linear approximations (Figure 2-13).  
 
Figure 2-13 Four transformed values (upper panel), and difference (in %) between four 
transformed values (lower panel), against proportion (P) from 0 to 0.15 
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To study the bias from the TRAU approximation in various sample sizes, simulation 
studies were performed. Scenarios include sample sizes 50, 100, 200, and 400, and event 
proportions between 0.01 and 0.50.  Based on 1000 simulation runs, the observed biases 
of TRAU (defined as TRAU – P *100) are tabulated in Table 2-3 and displayed 
graphically in Figure 2-14. The highest bias was 0.32% in the smallest sample size. 
 
Table 2-3 TRAU Bias (in %) from 1,000 simulation runs 
 N1 
               P2 50 100 200 400 
                      0.01 
                      0.05 
                      0.10 
                     0.20 
                     0.30 
                     0.40 
                     0.50 
-0.004 
0.082 
0.036 
0.140 
-0.1133 
0.3184 
0.0623 
0.034 
0.001 
0.075 
-0.047 
-0.2385 
-0.1120 
-0.1594 
0.014 
0.038 
0.019 
-0.040 
-0.0824 
0.0279 
0.0494 
-0.020 
-0.019 
0.018 
0.105 
-0.022 
-0.033 
-0.105 
1 Sample size used in simulations; 2 Underlying proportion used in simulations  
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Figure 2-14 TRAU bias estimates for sample sizes 50, 100, 200, and 400, obtained from 
1000 simulation runs. 
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simulations used above for biases. For illustrative purposes, TRAU was converted to 
proportions (i.e. divided by 100). Standard deviations from the simulations were 
tabulated in Table 2-4 and displayed graphically along with standard deviation obtained 
from the binomial formula in Figure 2-15. 
 
Table 2-4 Standard deviation estimates for TRAU based on simulations 
 N1 
P2 50 100 200 400 
0.01 
0.05 
0.10 
0.20 
0.30 
0.40 
0.50 
0.0799 
0.0817 
0.0719 
0.0733 
0.0719 
0.0725 
0.0704 
0.0647 
0.0530 
0.0499 
0.0509 
0.0485 
0.0496 
0.0485 
0.0446 
0.0365 
0.0353 
0.0347 
0.0356 
0.0360 
0.0353 
0.0282 
0.0262 
0.0255 
0.0249 
0.0242 
0.0252 
0.0256 
1 Sample size used in simulations; 2 Underlying proportion used in simulations 
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Figure 2-15 TRAU (in proportions) simulation standard deviations (red dashed line) 
obtained from 1000 runs vs. binomial standard deviation (blue solid line) for p <0.50 for 
sample sizes 50, 100, 200, and 400.  
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Although the empirical variances are nearly constant for proportions higher than 0.10, in 
particular, for large samples, the variance for small p (e.g. < 0.05) seemed higher than 
larger p for all sample size. The difference becomes small in large sample size situations 
(n > 400).  Since the focus of my research is low event proportion, I derive empirical 
variance estimate of TRAU based on parametric bootstrapping as following and used in 
simulations: 
• TRAU is a function of pˆ ,  
n
eventp =ˆ  
)ˆ,(~ pnBinomialevent  
 
• For a fixed sample size n and an estimated p of pˆ , we draw 1000 samples of events from 
binomial distribution and get 1000 pˆ samples. (If pˆ = 0, a small constant (e.g. 0.0001) 
was added) 
• The 1000 pˆ samples construct the distribution of the estimated pˆ from the original 
sample. Performed TRAU transformation for every pˆ sample and get 1000 TRAU 
samples.  These samples construct the empirical distribution of  TRAU computed from 
original data. Variance was obtained as the empirical variance estimate for TRAU. 
 
  
51 
 
 
 
2.6 PERFORMANCE 
 
These approximation methods can be used in analyzing 2 x 2 contingency table data for 
the evaluation of the risk differences. After the arcsine transformation of observed event 
proportion in each treatment group, the approximation methods are performed to provide 
percentage-like values for each treatment group. Similar to AD, the treatment effect 
measure is the difference between the approximation values from active and control 
groups. For example, in a hypothetical clinical trial of the flu vaccine (called treatment 
T), of 100 subjects who received T, 68 (i.e. observed proportion of 0.68) did not report 
any flu during the season. In comparison, only 23 (proportion of 0.23) out of 100 subjects 
who did not the vaccine (i.e. received control) did not have flu. The RAU for treatment T 
is 67.11% [ = 1.46*(31.83098861*2* Sin-1 68.0 -50)+50)]. For the control group, the 
RAU is 23.49% [ = 1.46*(31.83098861*2* Sin-1 23.0 -50)+50)]. Therefore, the 
treatment effect difference in RAUs between treatment and control: RAUD = 43.62%. 
Similarly we can obtain SAUD, MRAUD, and TRAUD for the differences in SAUs, 
MRAUs, and TRAUs between treatment and control groups. The performances of these 
effect measures in meta-analysis were evaluated in various simulation settings. 
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2.6.1 Inverse variance fixed effect meta-analysis 
 
One approach frequently used in meta-analysis in health care research is termed the 
'inverse variance method.’ With this method, the average effect size across all studies is 
computed as a weighted mean, whereby the weights are equal to the inverse variance of 
the effect estimate from each study. Larger studies and studies with less random variation 
are given greater weight than smaller studies. The weight assigned to each study is 
iY
i V
W 1= , 
where 
iY
V  is the within study variance for study (i). The weighted mean (M) of k studies 
is then computed as 
∑
∑
=
== k
i
i
k
i
ii
W
YW
M
1
1 , 
where Yi is the effect from study i, and i = 1, 2, …, k. The variance of the summary effect 
(M) is estimated as the reciprocal of the sum of the weights, or 
∑
=
= k
i
i
M
W
V
1
1 , 
and M is assumed to be normally distributed. This is a general method that can be used 
essentially in any effect measures. Therefore, I will use the inverse variance method as 
the basis for the performance evaluation of these approximation methods proposed. 
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2.6.2 Simulation settings and results 
 
For illustrative purposes, a standard study or trial with two parallel treatment groups (i.e. 
treatment vs. control) was used as the basic study design for simulations. The variable of 
interest is treatment difference between the treatment and control groups based on event 
proportions from the two groups. The simulation scenarios were selected to resemble a 
wide array of meta-analyses in scientific journals. For example, in the meta-analysis of 
rosiglitazone treatment effect on the risks of MI and death, Nissan and Wolski (2007) 
included a total of 42 clinical trials, with sample sizes ranging from 77 to 5,269. The 
subject assignments were un-equal allocations between active treatment and control, from 
4:1 to 1:2. Therefore, I used the following the parameters in simulations: 
k (number of studies (trials) included in a meta-analysis): 20, 40, 60, and 100; 
n (sample size for each study): obtained from lognormal distribution (7, 0.7), with mean 
value n of 1097; 
nt/nc (the sample size ratio between active, nt and control, nc groups): 2:1, 1:1, and 1:2;  
pc (event proportions from the control group): 0.01, 0.05, 0.10, and 0.15; 
RR (risk ratio between active and control groups): 1.5, 2, and 4. 
 
The event proportions reflect data of low to moderate event probability, and the choices 
of RR cover moderate to large differences between the active and control groups. These 
144 scenarios were simulated 1,000 times and the estimates for relative bias and 95% 
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confidence interval coverage were obtained. The relative bias was calculated as the ratio 
of the difference between simulation average and the true risk difference. The 95% 
confidence interval coverage was computed as the proportion of times when the true 
difference fell within the 95% confidence intervals based on the simulation results in 
1000 runs.  All simulations were carried out using software R 2.11.1 (R development core 
team, 2006) and package meta (Schwarzer, 2010). 
 
2.6.2.1 Relative bias 
Results of relative bias from these simulation scenarios are summarized in Table 2-5, for 
the meta-analysis of 20, 40, 60, and 100 studies, respectively.   
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Table 2-5 Summary of relative biases of RAUD, SAUD, MRAUD, and TRAUD 
K nt/nc Pc RR RAUD SAUD MRAUD TRAUD
20 2 0.01 1.5 3.651 2.165 1.193 0.113
2 3.135 1.813 0.949 0.039
4 2.224 1.194 0.520 -0.001
0.05 1.5 0.955 0.330 -0.079 0.028
2 0.806 0.229 -0.148 0.012
4 0.481 0.008 -0.056 0.002
0.1 1.5 0.427 -0.029 -0.264 0.018
2 0.325 -0.098 -0.006 0.007
4 0.126 -0.234 0.016 0.002
0.15 1.5 0.206 -0.179 0.224 0.013
2 0.132 -0.229 0.142 0.006
4 0.010 -0.313 0.013 0.002
1 0.01 1.5 3.285 1.916 1.020 -0.089
2 2.988 1.713 0.880 -0.062
4 2.177 1.162 0.498 -0.028
0.05 1.5 0.946 0.324 -0.082 -0.002
2 0.795 0.222 -0.154 -0.005
4 0.479 0.007 -0.058 -0.002
0.1 1.5 0.407 -0.043 -0.289 -0.007
2 0.318 -0.103 -0.012 -0.003
4 0.125 -0.234 0.016 0.000
0.15 1.5 0.196 -0.186 0.206 -0.002
2 0.127 -0.233 0.133 -0.001
4 0.010 -0.313 0.012 0.002
0.5 0.01 1.5 2.964 1.698 0.869 -0.328
2 2.823 1.601 0.802 -0.185
4 2.147 1.141 0.484 -0.065
0.05 1.5 0.911 0.300 -0.099 -0.049
2 0.786 0.215 -0.159 -0.023
4 0.476 0.004 -0.063 -0.007
0.1 1.5 0.407 -0.042 -0.303 -0.019
2 0.320 -0.102 -0.014 -0.007
4 0.126 -0.234 0.016 0.000
0.15 1.5 0.191 -0.189 0.195 -0.012
2 0.127 -0.233 0.130 -0.003
4 0.010 -0.313 0.011 0.002
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K nt/nc Pc RR RAUD SAUD MRAUD TRAUD
40 2 0.01 1.5 3.655 2.167 1.195 0.102
2 3.143 1.819 0.953 0.033
4 2.223 1.193 0.519 -0.003
0.05 1.5 0.947 0.325 -0.082 0.025
2 0.800 0.225 -0.151 0.010
4 0.482 0.008 -0.055 0.002
0.1 1.5 0.423 -0.031 -0.268 0.016
2 0.324 -0.099 -0.007 0.006
4 0.127 -0.233 0.017 0.002
0.15 1.5 0.199 -0.184 0.220 0.007
2 0.131 -0.230 0.141 0.005
4 0.010 -0.313 0.014 0.002
1 0.01 1.5 3.311 1.933 1.032 -0.098
2 2.944 1.684 0.860 -0.075
4 2.184 1.166 0.501 -0.029
0.05 1.5 0.927 0.311 -0.091 -0.012
2 0.797 0.223 -0.153 -0.005
4 0.478 0.006 -0.059 -0.003
0.1 1.5 0.416 -0.037 -0.287 -0.001
2 0.320 -0.101 -0.010 -0.002
4 0.125 -0.234 0.016 0.000
0.15 1.5 0.197 -0.186 0.208 -0.001
2 0.128 -0.232 0.134 0.000
4 0.009 -0.313 0.011 0.001
0.5 0.01 1.5 3.005 1.725 0.888 -0.329
2 2.809 1.592 0.796 -0.197
4 2.144 1.140 0.482 -0.069
0.05 1.5 0.913 0.302 -0.098 -0.048
2 0.785 0.214 -0.160 -0.025
4 0.478 0.005 -0.061 -0.006
0.1 1.5 0.409 -0.041 -0.305 -0.018
2 0.318 -0.103 -0.016 -0.008
4 0.125 -0.234 0.016 -0.001
0.15 1.5 0.192 -0.189 0.197 -0.011
2 0.128 -0.232 0.131 -0.003
4 0.009 -0.313 0.010 0.001
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K nt/nc Pc RR RAUD SAUD MRAUD TRAUD
60 2 0.01 1.5 3.659 2.170 1.197 0.115
2 3.124 1.807 0.944 0.028
4 2.223 1.193 0.519 -0.003
0.05 1.5 0.954 0.330 -0.079 0.028
2 0.802 0.226 -0.150 0.010
4 0.481 0.008 -0.056 0.002
0.1 1.5 0.422 -0.032 -0.269 0.015
2 0.325 -0.098 -0.006 0.007
4 0.127 -0.233 0.017 0.002
0.15 1.5 0.202 -0.182 0.222 0.009
2 0.130 -0.231 0.140 0.004
4 0.010 -0.312 0.014 0.003
1 0.01 1.5 3.293 1.921 1.024 -0.104
2 2.941 1.682 0.858 -0.077
4 2.176 1.161 0.497 -0.032
0.05 1.5 0.943 0.322 -0.084 -0.005
2 0.792 0.220 -0.155 -0.007
4 0.480 0.007 -0.057 -0.002
0.1 1.5 0.413 -0.039 -0.288 -0.003
2 0.320 -0.102 -0.010 -0.002
4 0.126 -0.234 0.016 0.000
0.15 1.5 0.201 -0.183 0.213 0.002
2 0.128 -0.232 0.134 0.000
4 0.010 -0.313 0.012 0.001
0.5 0.01 1.5 2.983 1.710 0.878 -0.341
2 2.836 1.610 0.809 -0.200
4 2.145 1.140 0.483 -0.070
0.05 1.5 0.917 0.304 -0.097 -0.046
2 0.786 0.216 -0.159 -0.023
4 0.476 0.005 -0.062 -0.007
0.1 1.5 0.411 -0.040 -0.304 -0.016
2 0.319 -0.102 -0.016 -0.008
4 0.125 -0.234 0.016 -0.001
0.15 1.5 0.196 -0.186 0.201 -0.008
2 0.127 -0.233 0.130 -0.004
4 0.010 -0.313 0.011 0.002
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K nt/nc Pc RR RAUD SAUD MRAUD TRAUD
100 2 0.01 1.5 3.644 2.160 1.189 0.105
2 3.126 1.808 0.945 0.032
4 2.226 1.195 0.521 -0.002
0.05 1.5 0.953 0.329 -0.079 0.028
2 0.803 0.227 -0.150 0.011
4 0.481 0.008 -0.056 0.002
0.1 1.5 0.421 -0.033 -0.270 0.014
2 0.324 -0.099 -0.006 0.007
4 0.126 -0.234 0.017 0.002
0.15 1.5 0.200 -0.183 0.222 0.009
2 0.130 -0.231 0.141 0.004
4 0.010 -0.313 0.013 0.002
1 0.01 1.5 3.289 1.919 1.022 -0.109
2 2.968 1.700 0.871 -0.070
4 2.175 1.160 0.497 -0.033
0.05 1.5 0.933 0.315 -0.089 -0.010
2 0.794 0.221 -0.155 -0.007
4 0.479 0.006 -0.058 -0.002
0.1 1.5 0.418 -0.035 -0.286 0.000
2 0.321 -0.101 -0.010 -0.002
4 0.126 -0.234 0.016 0.001
0.15 1.5 0.197 -0.186 0.209 -0.001
2 0.129 -0.232 0.135 0.001
4 0.010 -0.313 0.012 0.002
0.5 0.01 1.5 3.011 1.729 0.891 -0.343
2 2.821 1.600 0.801 -0.212
4 2.141 1.137 0.481 -0.075
0.05 1.5 0.915 0.303 -0.097 -0.048
2 0.786 0.215 -0.159 -0.025
4 0.475 0.004 -0.063 -0.008
0.1 1.5 0.408 -0.042 -0.307 -0.019
2 0.318 -0.103 -0.016 -0.009
4 0.125 -0.234 0.016 -0.001
0.15 1.5 0.194 -0.187 0.199 -0.009
2 0.128 -0.233 0.131 -0.003
4 0.009 -0.313 0.011 0.001
Notes: k = # of studies included meta-analysis; nt = sample size of the active treatment   
           group; nc = sample size of the control group; pc = underlying event proportion in   
           controls; RR = underlying risk ratio.  
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These relative biases are also depicted in Figures 2-16 – 2-19, for the meta-analysis of 20, 
40, 60, and 100 studies, respectively. Each figure contains 9 sub-plots, showing results 
from 36 different scenarios.  
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Figure 2-16 Relative bias of RAUD, SAUD, MRAUD, and TRAUD in meta-analysis of 
20 studies, with event proportion in control group 0.01, 0.05, 0.10, and 0.15. Ratio 
represents the subject allocation between treatment and control groups (2 = 2:1; 1 = 1:1; 
and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and control 
groups. 
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Figure 2-17 Relative bias of RAUD, SAUD, MRAUD, and TRAUD in meta-analysis of 
40 studies, with event proportion in control group 0.01, 0.05, 0.10, and 0.15. Ratio 
represents the subject allocation between treatment and control groups (2 = 2:1; 1 = 1:1; 
and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and control 
groups. 
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Figure 2-18 Relative bias of RAUD, SAUD, MRAUD, and TRAUD in meta-analysis of 
60 studies, with event proportion in control group 0.01, 0.05, 0.10, and 0.15. Ratio 
represents the subject allocation between treatment and control groups (2 = 2:1; 1 = 1:1; 
and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and control 
groups. 
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Figure 2-19 Relative bias of RAUD, SAUD, MRAUD, and TRAUD in meta-analysis of 
100 studies, with event proportion in control group 0.01, 0.05, 0.10, and 0.15. Ratio 
represents the subject allocation between treatment and control groups (2 = 2:1; 1 = 1:1; 
and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and control 
groups. 
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Under low event proportions from both treatment groups (e.g. pc ≤ 0.10 and RR < 4), as 
expected, the RAUD had the largest relative bias among the four methods, reaching 
approximately 3 or larger when the event proportion in controls was 0.01 and RR of 1.5 
between active and control groups. In contrast, the relative biases from SAUD are 
considerably smaller, ranging from 2.17 to 0.31 when the pc is low. However, when event 
proportions in both groups exceed 0.15, the relative biases in SAUD are higher than those 
from the RAUD. Among the linear approximation methods, the MRAUD performs the 
best (< 1.2 under all cases), with larger relative biases occurring when pc is low, and the 
difference between the two treatment groups is small. In comparison, the TRAUD has 
virtually the smallest relative biases under all scenarios examined. The maximum reached 
-0.34, when the event proportions are low in both groups, and treatment assignment of 
1:2.  
 
There were no appreciable trends in relative bias of any of the four methods for different 
numbers of studies examined, suggesting the performance of the approximations are 
independent of the size of meta-analysis.  Different treatment allocations did not seem to 
result in changes in relative biases of RAUD, SAUD, and MRAUD. But for TRAUD, the 
relative biases tended to move toward negative when the allocation ratio between active 
and control groups are 1:1 or 1:2. For the linear based methods, underlying risk and RR 
determined the magnitudes of the relative bias, suggesting biases are related to risk level 
as well as the difference between the two groups. For instance, in meta-analysis of 40 
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studies, equal sample size allocation, with RR of 2, the relative biases for RAUD were 
2.94, 0.80, 0.32, and 0.13 for event proportions in control 0.01, 0.05, 0.10, and 0.15, 
respectively. Similarly, with the same setting, the relative biases for MRAUD were 0.86, 
-0.15, -0.01, and 0.13, respectively. While the same trend, the changes in relative biases 
of TRAUD were less dramatic, e.g. -0.075, -0.05, -0.02, <0.001, respectively for the same 
settings. The RR indicates the differences in risk level between active and control groups, 
the larger the RR, the smaller the relative bias for all four methods. 
 
2.6.2.2 Coverage probability 
 
Complete 95% coverage probability results from simulations based on the 144 scenarios 
are provided in section 2.9 Appendix, and depicted in Figures 2-20 – 2-23, for meta-
analysis of 20, 40, 60, and 100 studies, respectively. Each figure contains 9 sub-plots, 
showing results from 36 different scenarios.  
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Figure 2-20 95% coverage probability of RAUD, SAUD, MRAUD, and TRAUD in 
meta-analysis of 20 studies, with event proportion in control group 0.01, 0.05, 0.10, and 
0.15. Ratio represents the subject allocation between treatment and control groups (2 = 
2:1; 1 = 1:1; and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and 
control groups. 
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Figure 2-21 95% coverage probability of RAUD, SAUD, MRAUD, and TRAUD in 
meta-analysis of 40 studies, with event proportion in control group 0.01, 0.05, 0.10, and 
0.15. Ratio represents the subject allocation between treatment and control groups (2 = 
2:1; 1 = 1:1; and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and 
control groups. 
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Figure 2-22 95% coverage probability of RAUD, SAUD, MRAUD, and TRAUD in 
meta-analysis of 60 studies, with event proportion in control group 0.01, 0.05, 0.10, and 
0.15. Ratio represents the subject allocation between treatment and control groups (2 = 
2:1; 1 = 1:1; and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and 
control groups. 
Coverage probability vs. pc (k=60)
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Figure 2-23 95% coverage probability of RAUD, SAUD, MRAUD, and TRAUD in 
meta-analysis of 100 studies, with event proportion in control group 0.01, 0.05, 0.10, and 
0.15. Ratio represents the subject allocation between treatment and control groups (2 = 
2:1; 1 = 1:1; and 0.5 = 1:2). RR (Relative Risk) represents the RR between treatment and 
control groups. 
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As shown, in general the 95% coverage probabilities from the three linear approximation 
methods are poor in most scenarios examined. Only at certain conditions one of the three 
methods reaches the nominal level, indicating that the coverage is dependent on the 
underlying proportions from both control and treatment groups. In comparison, the 
coverage probabilities from the TRAUD show consistently above or near the nominal 
level in majority of the scenarios.  
 
The RAUD coverage probabilities are generally low when the event proportions in the 
control group are at 0.10 and below. The coverage probabilities reach (or close to) the 
nominal 95% When the event proportion in the control group is 0.15, and RR of 4, 
indicating it only performs well when the event proportions are within the mid-range. 
This is consistent with the discussions in section 2.4.1 that the RAU approximation 
provides reasonable values when the event proportions are within 0.15 and 0.85. Both the 
number of studies included in a meta-analysis and the treatment allocations did not 
appear to impact the RAUD coverage performance.     
 
For the SAUD, higher coverage probabilities (between 79.4% and 95.0%) occurred when 
the event proportions for the controls are 0.05 and 0.10, vs. 0.20 and 0.15, respectively in 
the active group. This indicates the SAUD has better approximations than RAUD when 
the event proportions are between 0.05 and 0.20. The coverage performance is markedly 
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worse when the proportions fall outside the range. Similar to the RAUD, both the number 
of studies and treatment allocations did not seem to impact the results.   
 
While the coverage probabilities for MRAUD are slightly better than those from RAUD 
and SAUD in certain scenarios, its performance also heavily depends on the underlying 
event proportions in both the control and treated groups. For example, the coverage 
probabilities reach 70% and above when event proportion in controls is 0.05 vs. 0.075 in 
actives. This indicates the MRAUD can provide biased estimates for RD when the event 
proportion is outside its range.   
 
In comparison, the coverage probabilities from TRAUD are consistent and higher in 
nearly all situations. In cases when both the event proportion in the control group and the 
RR are low (e.g. pc = 0.01, and RR = 1.5), the TRAUD coverage probability can be 
reduced to below 90%. In extreme cases, when only one third of subjects receive active 
treatment, two third are control subjects, with event proportion on control of 0.01, and 
RR of 1.5, the coverage can drop as low as 25% for a meta-analysis of 100 studies.  
Noticeably, the number of studies included meta-analysis showed inverse relationship 
with TRAUD coverage probability. This may be due to the fact that smaller variance 
estimate was obtained because of the large number of studies included, which, in turn 
resulted in narrower 95% confidence intervals in simulations. The narrow range is 
sensitive to estimation bias introduced through approximation. In general, the results 
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show that except the situations where the event proportions are extremely low in both 
treatment groups, the coverage probabilities for TRAUD can reach the nominal level. 
This indicates the non-linear approximation performed well regardless of treatment 
allocation, and provides a viable alternative in analyzing data of low to moderate event 
proportions.   
 
2.7 DISCUSSIONS 
 
The use of arcsine transformation in binary data meta-analysis is reported to be limited in 
the literature, mostly because of the difficulties with interpretation of the results. The idea 
of converting the arcsine values to a percentage-like quantity is appealing, and may 
promote the utilization of the arcsine transformation. While the linear approximations can 
maintain statistical properties of the arcsine transformation, and are simple to implement, 
bias can be introduced and confidence interval coverage probability can be reduced. 
Based on the 144 simulation scenarios examined for moderate to low event proportions in 
the control group, the relative biases introduced from the RAUD, SAUD, and the 
improved method (i.e. MRAUD) were substantial in most scenarios, especially when the 
event proportion in the control is low, and the difference between the active and control 
groups is small (small RR). For example, in meta-analysis of 20 trials of equal sample 
size allocation between treatment and control, the event proportion for control was 0.01, 
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vs. 0.02 for the active group (i.e. RR=2.0). The relative biases were 2.99, 1.71, and 0.88, 
for RAUD, SAUD, and MRAUD, respectively. These biases (over-estimation) also 
resulted in nearly zero 95% coverage probabilities for these three linear approximations. 
When the event proportion from control was 0.15, with RR of 4.0, the relative biases 
were 0.01, -0.313, and 0.012, for RAUD, SAUD, and MRAUD, respectively. The biases 
from both RAUD and MRAUD were moderate with regard to the true underlying risk 
differences. It should be noted that both the relative bias and 95% coverage probability 
can change drastically in these linear approximations at different control event 
proportions. This is caused by the fact that, for certain ranges of the proportion, they can 
under-estimate, while in other regions, they may over-estimate. This limitation of these 
linear approximation methods should be carefully evaluated, in particular when the event 
proportions in controls and actives are within the ranges discussed in section 2.6.2.2 for 
different approximation methods. 
 
In comparison, the non-linear approximation obtained from Taylor series theorem 
(TRAUD) showed higher and consistent performance in terms of both relative bias and 
coverage probability in majority of the scenarios studied. While the approximation 
formula is more complex, it only involves elementary operations. However, unlike linear 
approximation, there is no apparent variance estimate. The empirical variance obtained 
via parametric bootstrapping appears adequate for risk estimation.  
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There are limitations in evaluations of these proposed methods. As specified in 
simulation settings, my research focused on moderate to low event proportions from the 
control group (≤ 0.15) as is commonly seen in safety data analysis. With a RR of 4.0, the 
event proportion from active group reached maximum at 0.60. Although the simulation 
evaluations did not cover the entire domain of event proportion, the linear approximation 
methods are symmetrical around 50%. Therefore, similar results may be assumed for 
event proportions outside the range studied. In addition, the meta-analyses were 
simulated using the inverse variance fixed effect method for homogeneous trials. 
Potential issues related to heterogeneity among studies have not been examined.        
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2.8 CONCLUSIONS 
 
The use of the arcsine transformation in analyzing binary data in meta-analysis has been 
proposed recently, in particular in situations of rare events that can result in zero cells in a 
2 x 2 table.  As an attempt to improve the interpretability of the arcsine transformation 
value, a modified linear (MRAU) and a non-linear approximation (TRAU) method were 
proposed in this dissertation to convert the arcsine value to a percentage-like quantity. 
The MRAU was obtained by modifying an existing approximation (RAU) for proportions 
outside of 0.15 and 0.85, where the RAU can differ significantly from the true 
proportions. The TRAU was derived from the Taylor series expansion by approximating 
percentages from arcsine values. These two approximation methods along with two 
existing linear approximation methods (RAU and SAU) were applied in meta-analysis 
simulations of two parallel treatment groups with a binary outcome. The treatment 
differences between active and control groups in these units (noted as RAUD, SAUD, 
MRAUD, and TRAUD) were evaluated in various simulation settings. The scenarios 
were designed to mirror commonly reported meta-analysis results of safety findings. 
Results from relative bias and 95% coverage probability showed that the three linear 
approximation methods can be considerably biased and have very low 95% confidence 
interval coverage probability except in limited situations where the underlying event 
proportions are at a certain range. The ranges are different based on the approximation 
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methods. Although compared to RAUD and SAUD, MRAUD had reduced relative bias 
and increased 95% coverage probabilities in some settings; its performance was not 
satisfactory in most scenarios studied. Thus it may be of limited utility where the event 
proportions are low. In comparison, with empirical variance estimate, the non-linear 
approximation (TRAUD) out-performed the linear approximations in nearly all 
situations. The relative bias was low and the 95% confidence interval coverage 
probability reached (or was very close to) the nominal level under most conditions. 
Therefore, TRAUD can be used as a tool of solving the lack of interpretability of arcsine 
transformation, which may lead to broader utility of AD in meta-analysis of binary data.    
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2.9 APPENDIX 
Coverage probabilities of RAUD, SAUD, MRAUD, and TRAUD from simulations 
k nt/nc pc RR RAUD SAUD MRAUD TRAUD 
20 2 0.01 1.5 0.323 0.264 0.014 0.878
20 2 0.01 2 0.004 0.01 0 0.927
20 2 0.01 4 0 0 0 0.957
20 2 0.05 1.5 0.078 0.452 0.717 0.945
20 2 0.05 2 0 0.196 0.434 0.944
20 2 0.05 4 0 0.932 0.527 0.951
20 2 0.1 1.5 0.154 0.916 0.086 0.931
20 2 0.1 2 0.001 0.315 0.529 0.95
20 2 0.1 4 0.001 0 0.12 0.95
20 2 0.15 1.5 0.463 0.099 0.003 0.941
20 2 0.15 2 0.22 0 0 0.936
20 2 0.15 4 0.965 0 0.131 0.949
20 1 0.01 1.5 0.347 0.29 0.037 0.898
20 1 0.01 2 0.005 0.009 0.001 0.909
20 1 0.01 4 0 0 0 0.925
20 1 0.05 1.5 0.063 0.43 0.727 0.944
20 1 0.05 2 0 0.188 0.341 0.936
20 1 0.05 4 0 0.95 0.51 0.957
20 1 0.1 1.5 0.141 0.916 0.057 0.949
20 1 0.1 2 0.001 0.23 0.569 0.946
20 1 0.1 4 0.001 0 0.146 0.944
20 1 0.15 1.5 0.46 0.053 0.005 0.94
20 1 0.15 2 0.204 0 0 0.968
20 1 0.15 4 0.959 0 0.163 0.95
20 0.5 0.01 1.5 0.503 0.44 0.075 0.703
20 0.5 0.01 2 0.023 0.035 0.003 0.751
20 0.5 0.01 4 0 0 0 0.834
20 0.5 0.05 1.5 0.109 0.539 0.774 0.924
20 0.5 0.05 2 0 0.232 0.364 0.939
20 0.5 0.05 4 0 0.937 0.507 0.939
20 0.5 0.1 1.5 0.199 0.914 0.066 0.933
20 0.5 0.1 2 0.006 0.276 0.544 0.953
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20 0.5 0.1 4 0.001 0 0.183 0.943
20 0.5 0.15 1.5 0.551 0.075 0.007 0.942
20 0.5 0.15 2 0.255 0 0.001 0.942
20 0.5 0.15 4 0.969 0 0.21 0.955
 
40 2 0.01 1.5 0.05 0.046 0.004 0.848
40 2 0.01 2 0 0 0 0.88
40 2 0.01 4 0 0 0 0.937
40 2 0.05 1.5 0.001 0.209 0.769 0.927
40 2 0.05 2 0 0.029 0.092 0.936
40 2 0.05 4 0 0.924 0.227 0.941
40 2 0.1 1.5 0.009 0.911 0.004 0.94
40 2 0.1 2 0 0.067 0.554 0.939
40 2 0.1 4 0 0 0.032 0.952
40 2 0.15 1.5 0.147 0.002 0 0.957
40 2 0.15 2 0.016 0 0 0.942
40 2 0.15 4 0.918 0 0.049 0.932
40 1 0.01 1.5 0.069 0.07 0.006 0.855
40 1 0.01 2 0 0 0 0.856
40 1 0.01 4 0 0 0 0.899
40 1 0.05 1.5 0.001 0.179 0.773 0.943
40 1 0.05 2 0 0.015 0.065 0.954
40 1 0.05 4 0 0.946 0.219 0.959
40 1 0.1 1.5 0.004 0.9 0 0.948
40 1 0.1 2 0 0.038 0.587 0.945
40 1 0.1 4 0 0 0.062 0.951
40 1 0.15 1.5 0.111 0 0 0.946
40 1 0.15 2 0.011 0 0 0.961
40 1 0.15 4 0.922 0 0.074 0.943
40 0.5 0.01 1.5 0.152 0.145 0.015 0.583
40 0.5 0.01 2 0 0 0 0.589
40 0.5 0.01 4 0 0 0 0.724
40 0.5 0.05 1.5 0.003 0.241 0.803 0.906
40 0.5 0.05 2 0 0.039 0.07 0.916
40 0.5 0.05 4 0 0.938 0.296 0.946
40 0.5 0.1 1.5 0.014 0.891 0.001 0.943
40 0.5 0.1 2 0 0.061 0.581 0.94
40 0.5 0.1 4 0 0 0.089 0.948
40 0.5 0.15 1.5 0.187 0 0 0.95
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40 0.5 0.15 2 0.019 0 0 0.954
40 0.5 0.15 4 0.939 0 0.134 0.947
60 2 0.01 1.5 0.003 0.006 0 0.832
60 2 0.01 2 0 0 0 0.863
60 2 0.01 4 0 0 0 0.938
60 2 0.05 1.5 0 0.062 0.773 0.922
60 2 0.05 2 0 0.001 0.017 0.927
60 2 0.05 4 0 0.911 0.087 0.948
60 2 0.1 1.5 0.001 0.883 0 0.937
60 2 0.1 2 0 0.013 0.567 0.943
60 2 0.1 4 0 0 0.019 0.932
60 2 0.15 1.5 0.03 0 0 0.93
60 2 0.15 2 0.001 0 0 0.938
60 2 0.15 4 0.873 0 0.013 0.939
60 1 0.01 1.5 0.006 0.008 0 0.828
60 1 0.01 2 0 0 0 0.821
60 1 0.01 4 0 0 0 0.875
60 1 0.05 1.5 0 0.041 0.778 0.952
60 1 0.05 2 0 0.002 0.003 0.951
60 1 0.05 4 0 0.922 0.101 0.947
60 1 0.1 1.5 0 0.862 0 0.95
60 1 0.1 2 0 0.002 0.621 0.955
60 1 0.1 4 0 0 0.034 0.936
60 1 0.15 1.5 0.018 0 0 0.952
60 1 0.15 2 0.001 0 0 0.965
60 1 0.15 4 0.891 0 0.05 0.941
60 0.5 0.01 1.5 0.035 0.044 0.003 0.443
60 0.5 0.01 2 0 0 0 0.478
60 0.5 0.01 4 0 0 0 0.665
60 0.5 0.05 1.5 0 0.108 0.775 0.888
60 0.5 0.05 2 0 0.008 0.015 0.902
60 0.5 0.05 4 0 0.934 0.127 0.925
60 0.5 0.1 1.5 0.001 0.85 0.001 0.949
60 0.5 0.1 2 0 0.007 0.607 0.93
60 0.5 0.1 4 0 0 0.055 0.949
60 0.5 0.15 1.5 0.042 0 0 0.947
60 0.5 0.15 2 0.004 0 0 0.944
60 0.5 0.15 4 0.89 0 0.071 0.939
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100 2 0.01 1.5 0 0.001 0 0.778
100 2 0.01 2 0 0 0 0.838
100 2 0.01 4 0 0 0 0.944
100 2 0.05 1.5 0 0.005 0.762 0.914
100 2 0.05 2 0 0 0.002 0.925
100 2 0.05 4 0 0.899 0.009 0.943
100 2 0.1 1.5 0 0.846 0 0.937
100 2 0.1 2 0 0 0.61 0.94
100 2 0.1 4 0 0 0.006 0.952
100 2 0.15 1.5 0.001 0 0 0.941
100 2 0.15 2 0 0 0 0.936
100 2 0.15 4 0.791 0 0.007 0.925
100 1 0.01 1.5 0 0 0 0.785
100 1 0.01 2 0 0 0 0.777
100 1 0.01 4 0 0 0 0.803
100 1 0.05 1.5 0 0.003 0.718 0.949
100 1 0.05 2 0 0 0 0.944
100 1 0.05 4 0 0.912 0.015 0.928
100 1 0.1 1.5 0 0.817 0 0.961
100 1 0.1 2 0 0 0.622 0.948
100 1 0.1 4 0 0 0.009 0.94
100 1 0.15 1.5 0.001 0 0 0.947
100 1 0.15 2 0 0 0 0.95
100 1 0.15 4 0.781 0 0.01 0.943
100 0.5 0.01 1.5 0.002 0.003 0.001 0.249
100 0.5 0.01 2 0 0 0 0.272
100 0.5 0.01 4 0 0 0 0.484
100 0.5 0.05 1.5 0 0.01 0.692 0.848
100 0.5 0.05 2 0 0 0 0.873
100 0.5 0.05 4 0 0.947 0.015 0.912
100 0.5 0.1 1.5 0 0.793 0 0.913
100 0.5 0.1 2 0 0.001 0.636 0.93
100 0.5 0.1 4 0 0 0.018 0.951
100 0.5 0.15 1.5 0.002 0 0 0.929
100 0.5 0.15 2 0 0 0 0.94
100 0.5 0.15 4 0.824 0 0.03 0.942
Notes: K = # of studies included meta-analysis; nt = sample size of the active treatment 
group; nc = sample size of the control group; pc = underlying event proportion in 
controls; RR = underlying risk ratio.   
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3 FINITE MIXTURE MODEL APPROACH FOR 
HETEROGENEITY IN META-ANALYSIS OF STUDIES 
SUMMARY 
 
Heterogeneity in meta-analysis refers to variation in study outcomes above the level that 
would be expected due to the sample sizes of the individual studies. When there is 
evidence of non-homogeneous effects based on some measures, such as Cochran’s Q-
test, a random effects model is routinely used. These models allow the effects to vary 
between studies in a manner consistent with a single normal distribution (DerSimonian 
and Laird 1985). Nevertheless, the random effect model is not a cure for difficulty in 
generalizing results of a meta-analysis to real-world situations when the assumption of 
the effects from all studies following a single normal distribution may not hold. The finite 
mixture model (FMM) provides a natural representation of heterogeneity by assigning 
study results to a finite number of latent classes. It assumes essentially that studies come 
from different sub-populations in terms of the response of interest. This is particularly 
appealing in meta-analysis as often studies are conducted at different times, geographical 
locations, or with different patient populations. These and other observable and 
unobservable factors are all potential sources of heterogeneity. The FMM provides a 
framework for estimating the number of latent classes, allowing identification of 
homogeneous clusters of studies. This may provide insight into the underlying factors 
that influence intervention effects that random effect models do not directly address.    
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Recent developments in computational capability have made the mixture model 
methodologies accessible for broader utilization. My research includes reviews of current 
methods using both maximum likelihood and Bayesian hierarchical model based 
frameworks, and implementation in the setting of meta-analysis.  
 
3.1 INTRODUCTION 
 
The primary objective in meta-analysis is to obtain an overall estimate of effect across the 
collection of primary studies, such as odds ratio for a risk factor, or mean difference 
between treatments. The overall effects are obtained through either the fixed effect model 
or the random effects model. The underlying assumption for fixed effect model is that the 
studies included in a meta-analysis are a random sample of studies estimating the same 
true effect, δ, and that all differences in observed effects are entirely due to sampling 
error, which I will denote by ε. In contrast, the random effects model allows that the true 
effects vary from study to study. The assumption is that the studies included in a meta-
analysis have enough in common that it makes sense to combine the results from each 
study, but there is no assumption that they are all studies of exactly the same true effect. 
Therefore the random effects model is typically shown with two levels: the first level 
assumes the effect from each study (i) follows a normal distribution with mean δi and 
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sampling error, εi. The second level assumes that the δi are normally distributed with 
mean of true effect δ and variance of τ2. The parameter τ2 is the between study variance, 
which is the variance of the effect size parameter across the population of studies beyond 
what can be accounted for within the studies due to sampling error.  
 
It is worth noting that both methods assume there is an underlying true effect size δ that 
applies to all the studies included in a meta-analysis. The variability observed in the study 
results is due to sampling errors and the inter-study variance. However, there are many 
reasons to question these assumptions. For example, meta-analyses routinely include 
studies conducted at various times in different geographical locations, and with different 
patient populations. Each of these factors can play a major role in our interpretation of 
what the ‘true effect size’ means. In bio-medical research, with the advancement of 
science and technology over time, medical practice can change dramatically over time, 
coupled with differences in social and economic conditions across regions, countries, and 
patients. The assumption of a single true effect may not always be most appropriate in 
terms of providing information for our understanding of the effect of treatment. It has 
been argued that the ability to generalize meta-analysis results might be explored through 
additional analyses that incorporate specific predictive uncertainties on top of the 
intrinsic uncertainties of the studies under review (Ades and Higgins, 2005). Explorations 
of whether more than one sub-population exists within the studies contained in a meta-
analysis are worthy of consideration.  Recent development in FMM methodologies shows 
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some desirable capabilities for identifying the number of components and estimation of 
component parameters, which can provide the foundation for exploring heterogeneity in a 
meta-analysis setting.  
 
3.2 BACKGROUND AND REVIEW OF CURRENT METHODS 
3.2.1 Fixed Effect Model 
 
Under a fixed effect model, the studies included in a meta-analysis are assumed to be 
random samples of studies from a single true underlying effect size. The variability 
observed among studies is purely attributable to sampling errors. The fixed effect model 
provides the means of estimating the true effect. Let mi denote the measure of effect in 
study i,   
),(~,| 22 iii sNsm δδ  
where δ is the true effect size, and 2is  is the square of the standard error of the estimate 
mi, which equals to [SE(mi)]2. Since 95% of the confidence intervals contain δ, study 
effect sizes follow the funnel shape shown below (Figure 3-1) when plotted against the 
standard error. 
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Figure 3-1 Funnel plot of effect size vs. standard error. Each dot represents a study (mi), δ 
is the effect. 
 
Several methods are commonly used for fixed effect pooling. The inverse variance 
method estimates the true effect thorough weighted average of effect sizes from all 
studies. The weight assigned to each study is the inverse of the within-study variance for 
study (i). This method can be used with virtually all types of effect measures, such as 
mean difference, log odds ratio, arcsine difference, etc. Other fixed effect methods for 
pooling study results have been developed specifically for binary outcomes. The most 
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commonly used method for combining odds ratio is the Cochrane-Mantel-Haentzel 
method using each study as an individual stratum. The pooled estimate is calculated by 
∑
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where ai, bi, ci, and di are the four cells of the 2 x 2 table for the i = 1…k studies, and ni is 
the total number of subjects in the ith study. Another method, the Peto method (Yusuf, 
Peto, Lewis et al. 1985) is based on an approximation to the data likelihood, expressed as 
a difference between observed and expected counts to estimate the pooled log odds ratio. 
3.2.2 Heterogeneity 
 
As discussed in section 3.2.1, the key assumption for use of the fixed effect meta-analysis 
approaches is that all the primary studies are estimating exactly the same quantity, δ. 
Although the point estimate of the effect size from the different studies being considered 
will differ to some degree, the difference is purely due to sampling error (i.e. random 
variation). This is called the homogeneity assumption. Under this assumption, the fixed 
effect model ignores any heterogeneity among the studies. However, often the variability 
in effect size estimates exceeds that which could be expected from sampling error along, 
i.e. the true underlying effect size is not the same for all studies. Ioannidis et al. (2008) 
outlined the types of heterogeneity as: (i) clinical heterogeneity, the differences in how 
the studies in the meta-analysis were conducted. Factors include patient selection, 
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treatment administration, study type, types of control, and analysis performed; (ii) 
statistical heterogeneity, when the primary study effect sizes have greater variation than 
would be expected due to chance alone if they were all estimates of the same population 
value.   
 
Several methods have been developed to detect heterogeneity among studies in a meta-
analysis. It should be noted that null results from statistical heterogeneity tests might be 
due to low power for the tests; therefore, failure of a test for heterogeneity to reach 
significance should not be interpreted as solid proof of homogeneity. Some descriptive, 
non-test based diagnostic procedures for heterogeneity should be explored as the first step 
before testing. Funnel plots such as shown in Figure 3-1 are commonly used for this. 
Funnel plots have the effect size on the horizontal axis and the standard error of the effect 
size estimate, the precision of the estimate, or the sample size on the vertical axis. Under 
homogeneity, results from different studies should have a funnel shape. An example of 
single funnel plot is provided in Figure 3-1.  If the effect sizes are heterogeneous, there 
may be 2 (or more) funnel shapes superimposed in the funnel plot. Figure 3-2 shows a 
funnel plot of standardized mean differences for Risperidone treatment in 34 randomized 
clinical trials (Leucht et. al., 2009).  
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Figure 3-2 Funnel plot of standardized mean difference of overall symptoms between 2nd 
generation antipsychotic drug (Risperidone) and 1st generation drugs in schizophrenia.  
 
Another commonly used graph is called the “Forest Plot,” where both the study effect 
sizes and precision (through the width of the confidence intervals) are displayed. 
Heterogeneity is shown in this plot by studies that have very different effect sizes. In 
extreme cases, the confidence intervals can fail to overlap. This failure to overlap could 
be from a single outlying study, but if the studies can be sorted into groups with similar 
effect sizes and confidence intervals, then that would indicate statistical heterogeneity. 
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Several statistical tests have been developed to detect inter-study variability. The 
fundamental method is the Q-test statistic, together with several extensions. Q is the 
weighted sum of squares (WSS), defined as  
∑
=
−=
k
i
ii MYWQ
1
2 ,)(  
where Wi is the study weight (1/Vi), Vi is the variance of the ith study effect measure, Yi 
is the study effect size for the ith study, M is the fixed effect pooled estimate, and k is the 
number of studies. Under the null hypothesis of homogeneity, Q has a χ2 distribution with 
degrees of freedom equal to one less than the number of studies (k-1). A p-value can be 
obtained from a chi-square distribution to determine if the heterogeneity (i.e. excess 
variation) is significant. While simple and intuitive, this test depends on the number of 
studies.  When the number of studies in a meta-analysis is small, the statistical power of 
the Q-test becomes very low. In contrast, it can reject the null hypothesis even if there is 
little variation among a large number of studies. Another measure, the H statistic is 
defined as 
1−= k
QH
 
. 
Under homogeneity, the expected value of Q is k-1, therefore the H statistic has a mean 
value of 1. Higgins and Thompson (2002) propose that if H is more than 1.5 there should 
be considerable caution regarding heterogeneity. Even if the Q-test is not significant and 
H is less than 1.2, there should probably be little concern even if the Q-test is significant.  
A more refined measure, the I2 statistic is probably the most widely used measure, which 
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is a transformation of H
 
that estimates the proportion of the total variability in effect size 
that is due to the between study variation. It is defined as 
2
2
2 1
H
HI −= . 
 
 It was suggested that the value of I2 greater than 0.25 would indicate some level of 
heterogeneity and values above 0.75 would indicate large heterogeneity (Higgins et al., 
2003).  Two other measures used are estimates of τ2 and τ (Tau). These estimates directly 
measure the inter-study variability, equivalent to the variance and standard deviation of 
the true effects, on the same scale as the effects themselves. Therefore, they are 
dependent of scale used in effect measures. Further discussion and interpretation of τ2 are 
provided in the next section.  
3.2.3 Random Effects Model 
 
As an analysis technique that accounts for some level of heterogeneity, the random 
effects model is commonly recommended and used in meta-analysis. This was described 
by DerSimonian and Laird (1986) and is the basis of random effects meta-analysis. The 
random effects model assumes that the study specific effect sizes come from a normal 
distribution of effect sizes with a fixed mean and variance. This gives a model with two 
levels. As the first level, the study effect size estimate mi provides an unbiased estimate 
of the population effect size δi using the clinical set-up of study i, such as 
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At the second level, the population effect sizes δi have a normal distribution around some 
central value δ. Such as 
).,(~,| 22 τδτδδ Ni  
As described in measures of heterogeneity, the parameter τ2 is the inter-study variability. 
Estimation of τ2 is an important element of the random effects model because this 
variance explicitly describes the extent of the heterogeneity and has a crucial role in 
assessing the degree of consistency of effects across studies.  DerSimonian and Laird 
(1986) proposed an estimation method for τ2 based on the method of moments. It is 
computed using Q statistic in the following way: 
),(~,| 222 ii sNm +τδτδ  
C
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where df = k-1, and  
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Other estimators of τ2 are available that are based on normal likelihoods, including 
iterative maximum likelihood, restricted maximum likelihood, and weighted least-squares 
(DerSimonian and Laird, 1986, DerSimonian and Kacker, 2007, Sidak and Jonkman 
2005). 
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As in the fixed effect analysis, each study is weighted by the inverse of its variance to 
obtain an overall mean effect size. The difference is that under random effects model, the 
variance includes both the within studies and between studies variance components. In 
this way, although it does not explain the variability and still assumes there is a common 
mean δ applying to the studies included in a meta-analysis, the random effects model 
accommodates moderate heterogeneity. Because of this less stringent assumption and 
common presence of some level of heterogeneity in meta-analysis, the random effects 
analysis is performed routinely. For example, Bischoff-Ferrari et al. (2011) examined 
milk intake and risk of hip fracture in men and women via random effects model to 
account for moderate heterogeneity. They showed that in women (6 studies, 195102 
women, 3574 hip fractures), there was no overall association between total milk intake 
and hip fracture risk (pooled RR per glass of milk per day = 0.99; 95% confidence 
interval 0.96–1.02; Q-test p = 0.37).  
 
There have been concerns raised over the heavy dependence on the random effects model 
for meta-analyses. Higgins, Thompson, and Speigelhalter (2009) provided a re-evaluation 
of random effects meta-analysis where they discussed the justification and interpretation 
of the model by addressing the aims of estimation, prediction and hypothesis testing. A 
particular issue was the distinction between inference on the mean of the random-effects 
distribution and inference on the whole distribution. They argued that random-effects 
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meta-analyses as currently conducted often fail to provide the key results, and Bayesian 
approaches can provide more satisfactory methods. They concluded that the Bayesian 
approach has the advantage of naturally allowing for full uncertainty, especially for 
prediction. Another article by Ades, Lu, and Higgins (2005) focused on the interpretation 
of the random effects models used in meta-analysis to summarize heterogeneous 
treatment effects on the results of decision models. The authors’ analysis suggests that the 
mean treatment effect from a random-effects meta-analysis will only seldom be an 
appropriate representation of the efficacy expected in a future implementation of a 
treatment. Instead, decision modelers should consider either the predictive distribution of 
a future treatment effect, or they should assume that the future implementation will result 
in a distribution of treatment effects.  
 
The finite mixture model provides an alternative approach to the random effects model to 
address heterogeneity by relaxing the assumption of a single true underlying mean among 
all studies. In such a way that studies are grouped into homogenous sub-populations, 
estimations and inferences are performed separately for each of the groups (i.e. 
components of mixture).    
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3.2.4 Review of Finite Mixture Model Theory and Applications 
 
 
3.2.4.1 Introduction 
 
A mixture model is a probabilistic model for representing the presence of sub-populations 
within an overall population, without requiring that an observed data-set identify the sub-
population to which an individual observation belongs. Formally, a mixture model 
corresponds to the mixture distribution that represents the probability distribution of 
observations in the overall population. However, while problems associated with 
"mixture distributions" relate to deriving the properties of the overall population from 
those of the sub-populations, "mixture models" are used to make statistical inferences 
about the properties of the sub-populations (components).  Inferences derived from 
mixture models are based only on observations of the pooled population, without 
information that identifies membership in a sub-population. 
 
A Finite Mixture Model (FMM) assumes the number of components (m) in the mixture is 
a fixed constant and is not a parameter to be estimated. The general expression for FMM 
is as follows: 
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The mixture probability for jth component (or sub-population) is denoted as jπ and it can 
depend on regressor variables z and parameters jα . The component distribution for jth 
component is denoted as jp and it can depend on regressor variables in jx , regression 
parameters jβ , and possibly scale parameters jφ . In most settings, it is assumed that all 
component densities are independent, arise from the same parametric distribution family, 
and that πi (z, αj) follows a multinomial distribution. One simple application of the FMM 
is a two component Gaussian mixture such as: 
),;(),;()( 222111 σμφπσμφπ yyyf +=  
where ,0, 21 >ππ  12 1 ππ −= , iφ  is a normal density, 1μ  and 2μ are means for the two 
components with a common standard deviation of σ . The two-component Gaussian 
mixture can be easily expanded to accommodate an unequal variance situation. 
McLachlan et al. (2006) implemented a two component normal mixture model for 
microarray experiments with the goal to detect genes that are expressed differentially in a 
given number of classes through the use of test statistics. The first component of their 
mixture density corresponds to that of the test statistic for genes that are not differentially 
expressed, and the other component mixture density corresponds to that of the test 
statistic for genes that are differentially expressed. They demonstrated that a two-
component normal mixture model was adequate for modeling the empirical distribution 
of z-scores, where the first component was the standard normal density, corresponding to 
the null distribution of the scores, and the second component was a normal density with 
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un-specified (positive) mean and variance, corresponding to the non-null distribution of 
z-scores.  
 
In more complicated situations, the component distributions jp  can belong to different 
distributional families. For example, Atienza et al. (2008) analyzed the length of hospital 
stay as an important indicator of the hospital activity and management of health care. 
Because of the skewness and heterogeneity among diagnosis related groups exhibited in 
the variable distribution, a single parametric model was considered not be adequate. 
Therefore the authors modeled the data through a mixture of lognormal, Gamma, and 
Weibull family mixtures. The mixture distributions of the length of hospital stay (y) were 
defined as following: 
),;(),;(),;()( 332211 dcypbaypypyQ ππσμπ ++=  
where 1π ,  2π , 3π  > 0, 1π + 2π + 3π =1, ,21, pp and 3p belonged to lognormal, gamma, and 
Weibull distribution families, respectively, and μ, σ, a, b, c, and d were the corresponding 
distribution parameters. It was shown that the mixture model fit better than a single 
distribution model.  
 
It should be noted that the shape of a mixture density can be extremely flexible, 
depending on the underlying distribution type, the number of components, the location, 
the variability, and weight of each mixture component. Figure 3-3 shows the densities of 
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two-component normal mixture distributions. It demonstrates that a mixture density can 
have multimodal or uni-modal shape, be skewed, or be heavy in the middle. 
 
Figure 3-3 Densities of two-component mixture of normal distributions, with equal 
variance and various means. One of the two-components is a standard normal, combined 
with normals with means of 1.8, 2.5, and 3.5 from left to right, respectively. The two 
plots on the left are with equal weight, while the plot on the right is composed with 
weights of 0.77 and 0.23 for the two components, respectively.  
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As illustrated in figure 3-3, finite mixture models can be extremely flexible when used in 
capturing many specific features of real data, such as multimodality, skewness, and heavy 
tails. Therefore, FMM can be a useful tool in accounting for data heterogeneity.  
3.2.4.2 Methods of identifying number of components in a finite mixture 
 
While assumed to be a fixed constant, the determination of number of components in a 
finite mixture distribution is still an active research area, and it is considered as one of the 
major challenges in finite mixture analysis. As summarized by Fruhwirth-Schnatter 
(2006), three types of statistical inference for a finite mixture model need to be 
considered. First, modeling of data by a finite mixture model requires some specification 
of M, the number of components. Second, the component parameters need to be 
determined, such as distribution parameters of interest, or even regression parameters 1β , 
…, mβ and possibly even scale parameters 1φ , …, mφ in complex situations. Thirdly, the 
weight distribution π1 (z, α1), …, πm (z, αm) needs to be determined. The last inference is 
done by assigning each observation yi to a certain component and making inference on 
the hidden discrete allocation indicators. 
 
While there is substantial interest and research on estimating the number of components 
(i.e. M) in a mixture distribution, it is often impossible to assign a value to M with 
certainty. Statistical testing for the number of components in a mixture model is known to 
be a difficult problem. As discussed in detail by Fruhwirth-Schnatter (2006), several 
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informal methods have been used for identifying the number of components. The most 
straightforward method is to use the sample histogram or density plot. This can be 
appropriate for datasets where several modes are evident in the histogram or density plot, 
indicating the components in a mixture distribution are separated sufficiently and with 
limited overlap. For example, in the Old Faithful geyser eruption data analyzed by Hunter 
et al. (2007), a two-component mixture model is clearly reasonable based on the 
bimodality evident in the histogram (figure 3-4).  
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Figure 3-4 Histogram of eruption time of the Old Faithful geyser in Yellowstone National 
Park, USA.   
 
However, as shown earlier, in many situations, finite mixture distributions are uni-modal 
or show fewer modes than components in the empirical plot. Figure 3-5 shows simulation 
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densities of three component normal mixture distributions with sample sizes of 500 
observations. The means of the three components are 0, 2, and 4, with a common 
standard deviation of 1. Three different weights were applied to the components 
(displayed in the three rows) and three random samples (displayed in the three columns) 
were obtained in each situation. As shown in row 1, when the components have similar 
weights, the densities are somewhat suggestive of multiple components. Multiplicity of 
modes becomes less clear when the weight changes from equality. Obviously the 
distances among mixtures play a central role additionally. Nevertheless, this crude 
method is only for exploratory purposes. 
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Figure 3-5 Densities of three normal mixture distribution: N(0, 1), N(2, 1), and N(4, 1). 
First row shows equal weight 1:1:1 ratio among the three normal components, middle 
row shows 7:2:1 weight ratio, and last row shows 5:3:2 weight ratio. Three columns 
represent three random samples for each case. 
 
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
D
en
si
ty
 (w
ei
gh
t 1
:1
:1
) N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
D
en
si
ty
 (w
ei
gh
t 7
:2
:1
) N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
D
en
si
ty
 (w
ei
gh
t 5
:3
:2
) N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
N(0, 1)
N(2, 1)
N(4, 1)
-2 0 2 4 6
0.
00
0.
10
0.
20
0.
30
 
N(0, 1)
N(2, 1)
N(4, 1)
103 
 
 
 
Because of the limitations of graphical methods, several likelihood-based methods have 
been developed in finite mixture modeling. A maximum likelihood estimator πˆ of π is 
defined as a probability measure πˆ that maximizes the log likelihood of the density, 
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= . Two iterative optimization methods were proposed 
by Bohning (1995) and were discussed in detail by Schlattmann (2009). These methods 
rely on the concept of directional derivatives (i.e. gradient functions). The first one is 
called the vertex direction method (VDM), and other is the vertex exchange method 
(VEM). Both methods involve the selection of a grid of parameter values θ1, …, θm over 
which we wish to find the corresponding population proportions that maximize the 
likelihood function. This process is repeated for each fixed number of components within 
the pre-specified maximum number of components one wishes to explore. The final 
model is selected based on the likelihood statistics, which includes estimates for number 
of components, and the component parameters. For both algorithms, any sequence (πi) 
created with arbitrary initial value will converge toπˆ  in a monotonic and stable manner, 
but the VEM converges faster than VDM. Both strategies are implemented in the R 
package C.A.MAN (Computer Assisted Analysis of Mixtures: Bohning, Schlattmann, 
and Lindsay (1992), Bohning, Dietz, and Schlattmann (1998)). The VEM method was 
used in a meta-analysis of the association of Raynaud Syndrome with Thromboangiitis 
Obliterans, where four distinct components (sub-populations) were identified with 
different prevalence rates (Hartmann, et al. 2012).  
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With these algorithms provide estimates of M, there is a desire to find the most 
parsimonious model. First, as noted by Hartigan (1985), there are difficulties with 
applying the likelihood ratio (LR) statistics to testing the number of components, because 
the failure of the standard regularity conditions, on which the asymptotic χ2 distribution 
relies. The reason is that, if a model with M components (Mm) is compared to a model 
with M+1 components (Mm+1), Mm can be obtained from Mm+1 in more than one way. 
The number of constraints is equal to 1, when imposing the constraint 011 =++MMπ  on MM+1, 
and equal to dim( mθ ), when imposing the constraint 111 +++ = mmmm θθ . That is, it is only if the 
two finite mixture models differ in parameter structure but both assume the correct 
number of components, that the regularity conditions hold and the LR statistic may be 
applied in a straightforward manner (Fruhwirth-Schnatter, 2006).  
 
Various attempts have been made to modify the LR statistic to meet the regularity 
conditions so that an asymptotic χ2 distribution can be relied upon. Chen et al. (2001) 
considered mixtures with a univariate component parameter and a modified LR test for 
testing homogeneity (M=1) against heterogeneity (M>1) based on a penalized likelihood 
function. They showed that the resulting modified LR follows a mixture of a 21χ
distribution and a degenerate 20χ distribution under the null hypothesis of homogeneity. 
The authors (Chen et al. 2004) extended LR testing based on the penalized likelihood to 
testing the null hypothesis of M=2 vs. M>2, and showed that the asymptotic distribution 
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of this modified LR statistic is equal to a mixture of 20χ , 21χ , and 22χ distributions. These 
tests have been utilized infrequently because the lack of knowledge on the number of 
components in real situations.  
 
The bootstrap methods (Efron and Tibshirani, 1993) are powerful techniques that allow 
one to obtain estimates and assess the variability in random quantities using only the data 
sample available.  McLachlan et al. (1995) used a parametric bootstrap method to obtain 
the distribution of LR statistic for the test of null hypothesis H0: M=m1 versus H1: M=m2. 
The m1 and m2 are two different hypothesized number of components, can be used to 
compare any two different number of components. Two bootstrap samples (one under H0 
and one under H1) are generated where unknown parameters are replaced by their 
likelihood estimates. LR statistic is computed for each bootstrap sample under H0 and H1. 
The process is repeated B times to obtain the distribution of LR statistic. Inference then 
can be made based on the bootstrap distribution.  An alternative nonparametric bootstrap 
method was suggested and evaluated by Schlattmann (2005), based on bootstrap 
sampling with replacement from the available data. Using the VEM algorithm, an 
estimate of M is obtained in each bootstrap sample, and the mode of bootstrap 
distribution is used as the estimate for M. 
 
Often, readily available measures from standard statistical software are used in finite 
mixture modeling even though the regularity conditions may not be fully met. 
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Information criteria-based measures such as Akaike’s Information Criterion (AIC), 
Corrected AIC, and Schwarz’s Bayesian Information Criterion (BIC) have been used. 
Akaike (1974) used heuristic arguments on how to account for model complexity and 
proposed a general criterion for model choice 
AIC=2k – 2ln(L) 
where k is the number of parameters in the statistical model, and L is the maximized 
value of the likelihood function for the estimated model. Given a set of candidate models 
for the data, the preferred model is the one with the minimum AIC value. Hence AIC not 
only rewards goodness of fit, but also includes a penalty that is an increasing function of 
the number of parameters that need to be estimated. This penalty discourages over-fitting, 
as increasing the number of free parameters in a model will improve the goodness of fit, 
regardless of the number of free parameters in the data-generating process. The AIC 
estimate is simple, but is only valid asymptotically; if the number of data points is small, 
then some correction is often necessary. 
 
The AICc is AIC measure with a correction for finite sample sizes: 
1
)1(2
−−
++=
kn
kkAICAIC c  
where n denotes the sample size. Thus, AICc is AIC with a greater penalty for extra 
parameters. Burnham & Anderson (2002) strongly recommend using AICc, rather than 
AIC, if either n is small or k is large. Since AICc converges to AIC for large n, AICc 
generally should be employed rather than AIC. Using AIC, instead of AICc, when n is 
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not many times larger than k2, increases the probability of selecting models that have too 
many parameters, i.e. of over-fitting the model. AICc was first proposed by Hurvich & 
Tsai (1989). Different derivations of it are given by Brockwell & Davis (2009), Burnham 
& Anderson (2002), and Cavanaugh (1997). All the derivations assume a univariate 
linear model with normally distributed errors (conditional upon regressors); if that 
assumption does not hold, then the formula for AICc is changed.  
  
The BIC, developed by Gideon E. Schwarz (1978), is served as an asymptotic 
approximation to a transformation of the Bayesian posterior probability of a candidate 
model. In large-sample settings, the fitted model favored by BIC ideally corresponds to 
the candidate model which is a posteriori most probable; i.e., the model that is rendered 
most plausible by the data at hand. These terms are a valid large-sample criterion beyond 
the Bayesian context, since they do not depend on any particular prior distribution. The 
BIC is defined as 
BIC = -2Ln(L) + kLn(n) 
Given any two models fit to a set of data, the model with the lower value of BIC is the 
one to be preferred. The BIC generally penalizes free parameters more strongly than does 
the AIC, though it depends on the size of n and relative magnitude of n and k (for n ≥ 8, 
kLn(n) exceeds 2k). Consequently BIC tends to favor smaller models than AIC does. By 
choosing the fitted candidate model corresponding to the minimum value of BIC, one is 
attempting to select the candidate model corresponding to the highest Bayesian posterior 
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probability. The models being compared need not be nested, unlike the case when models 
are being compared using an F or likelihood ratio test. 
 
Heckman et al. (1990) proposed the use of the method of moments for estimating the 
unknown parameters in a finite mixture of exponentials and for estimating the number of 
components in mixing distribution. This method compares several theoretical moments 
implied by a mixture model with M components to the corresponding sample moments. 
Mixtures with different numbers of components are evaluated by the impact of increasing 
M has on reducing the discrepancy between the two moments. The difficulty with fitting 
a mixture model in this way is how to decide whether the effect of adding another 
component is significant (Fruhwirth-Schnatter, 2006). As shown by Monte Carlo 
simulations in Heckman et al. (1990), the method failed to identify a single case in 100 
samples in settings with two component and four component finite mixture distributions 
when the sample size was 100. The performance was slightly better in large sample size 
settings, with 6% correct identification rate in two component mixture setting when 
sample size was 10,000.  
 
Another method of mode hunting for diagnosing mixtures is to utilize the mixture 
posterior density (Fruhwirth-Schnatter, 2001b). This method is based on the observation 
that with an increasing number of observations, the mixture likelihood function has M! 
dominant modes if the data actually arise from a finite mixture distribution with M 
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components, and that less than M! dominant modes are present if the finite mixture 
model is over-estimating the number of components (Fruhwirth-Schnatter, 2006). 
Practically, the number of modes is determined by exploring the sampling representation 
of the mixture posterior density, by drawing from the mixture posterior using the random 
permutation Gibbs sampler. For example, for a three component mixture, it would 
indicate too many components if less than 6 dominant modes are present. 
 
Other methods of diagnosing mixtures through Bayesian posterior predictive models are 
by Gelfand et al. 1992 and Gelman et al. 1996.  
3.2.4.3 Estimation methods of component parameters in a finite mixture 
with known allocation 
 
With known allocation, i.e. knowing the component membership of all observations in 
the data, both maximum likelihood and Bayesian estimation can be based on the 
complete data likelihood. With maximum likelihood, given a sample size N of 
yi 
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With Gj being the density of component j, and the maximum likelihood estimate is 
)(maxargˆ θθ θ Lmle = . 
110 
 
 
 
Thus, complete data ML estimator for the weights for m=1, …, M, 
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The ML estimators of the mixture distributions depend on the underlying parametric 
family as the component density. For mixtures of normal distributions, the ML of mμ  and 
2
mσ  are the sample mean and sample variance in group m, such as 
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In Bayesian estimation, of the complete likelihood L(θ) is combined with a prior 
distribution p(θ) on the parameter θ to obtain the complete data posterior distribution p(θ | 
y, G) using Bayes’ theorem.  
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Fruhwirth-Schnatter (2006) discussed in some details about the choice of prior for 
Bayesian estimation of the weights, including the uses of Dirichlet distribution, Jeffreys’ 
prior, and improper priors. In commonly encountered situations, such as binary or 
multinomial data, Bayesian estimates tend to be sensitive to the choice of prior, when 
some of the observed categories are rare. Otherwise the estimates are insensitive to the 
choice of prior. Therefore, considerations should be made in cases when one suspects 
extreme unbalance of among components. 
3.2.4.4 Parameter estimation in a finite mixture when the allocations are 
unknown 
 
When the component parameters θ1, …, θm, the weight distribution π, and the allocation 
G are all unknown, the estimation of the mixture parameters is complex. Even for 
mixtures of standard distributions such as the normal distribution no explicit estimation 
method exists, and numerical methods are required for practical estimation.  
 
With the advancement of computing capabilities, the expectation-maximization (EM) 
algorithm (Dempster et al. 1977) is the most commonly applied method for ML 
estimation for finite mixture models. It is based on the idea of replacing one difficult 
likelihood maximization with a sequence of easier maximizations whose limit is that 
answer to the original problem. It is particularly suited to “missing data” situations, 
because the presence of missing data can make likelihood calculations cumbersome. The 
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use of the EM algorithm for the estimation of wide range of finite mixture models has 
been discussed in details in Redner and Walker (1984), Meng (1997), and McLachlan 
and Peel (2000).  As summarized in Fruhwirth-Schnatter (2006), the implementation of 
the EM algorithm starts with the log of complete-data likelihood function p(y, G|θ). 
log p(y, G|θ)=∑∑
= =
N
i
M
m
mimim ypD
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where imD is a 0/1 coding of the allocations such that iG : imD =1, iff iG =m. Starting 
from )0(θˆ , the EM algorithm iterates between two steps: an E-step, where the conditional 
expectation of logp(y, G|θ), given the current data and given the current parameter values 
are computed, and an M-step in which parameters that maximize the expected complete 
data log likelihood function, obtained from the E-step are determined. For mixture 
models, the E-step leads to the following estimator of the imD , 
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And the M-step involves maximizing 
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with respect to all unknown components in θ = (θ1, …, θm, π), leading to a new estimate 
)(ˆ mθ . For an arbitrary mixture 
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whereas the estimator of the component parameters θm depends on the distribution family 
underlying the mixture. For a univariate mixture of normal distributions, 
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One major advantage of the EM algorithm is that it always converges, but it may be slow 
and converge to a local maximum instead of to the global maximum. The CAMAN 
package implements the EM algorithm along with an improved algorithm using gradient 
update. Schlattmann (2009) proposed a hybrid mixture algorithm combining the VEM 
algorithm for flexible support size and the EM algorithm, where the solution of VEM 
provides starting values for the EM algorithm.  
 
Bayesian inference under model uncertainty was discussed at length in Fruhwirth-
Schnatter (2006).  There are basically two Bayesian approaches for a finite mixture 
model. The first is trans-dimensional Bayesian inference, that assumes K alternative 
models, M1, …, Mk should be evaluated, given data y=(y1, …, yN). Each model Mk is 
specified in terms of a sampling distribution p(y|θk, Mk) and a prior distribution p(θk|Mk), 
where θk Є Θk denotes the collection of all unknown model parameters, including the 
number of components in a finite mixture. Bayesian inference is considered as joint 
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inference about the model indicator and all model parameters θ1, …, θk, given data y. 
This is carried out by deriving the posterior distribution p(Mk, θ1, …, θk|y) using Bayes’ 
theorem: 
p(Mk, θ1, …, θk|y) ∝  p(Mk, θ1, …, θk) p(θ1, …, θk| Mk)p(Mk). 
Normally Bayesian inference has to rely on Markov chain Monte Carlo (MCMC) 
methods due to the fact that there are rarely analytic forms for such posterior 
distributions. The MCMC methods use a Markov chain to obtain draws from the joint 
posterior, move through the model space Ω = { M1, …, Mk} during sampling and, 
marginally, provide draws from the discrete posterior distribution p(Mk|y). 
 
The second approach is to compute all possible models of the marginal likelihood p(y|Mk) 
and apply Bayes’ rule to quantify posterior evidence in favor of each model.  The 
computation of the marginal likelihood for a finite mixture model is difficult, and usually 
relies on simulation based approaches.    
 
3.3 FINITE MIXTURE MODEL APPLICATIONS IN META-
ANALYSIS 
As discussed in Section 3.2.2, there are many potential sources of heterogeneity in meta-
analysis. Simply pooling to obtain an overall estimate with the fixed effect model or the 
random effects model may not be adequate, and could be misleading if the studies 
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represent a mixture distribution. Finite mixture modeling can be a useful alternative when 
the assumption of single underlying distribution for all studies is questionable. It also 
provides a framework for identifying latent subpopulations within a meta-analysis that 
may be important for the understanding of the true nature of the therapy or exposure 
under investigation. 
3.3.1 Maximum likelihood methods 
 
In a meta-analysis composed of k individual studies, assume there are m underlying 
subpopulations (i.e. the number of components in a mixture model), such that the study 
estimates 1ˆθ , 2ˆθ , …, kθˆ  come from θj, j=1, 2, …, m. Further, assume the effect from an 
individual study follows a normal distribution, such as 
mjkif
i
ji
i
ji ,...,1,,...,1,2
)ˆ(
exp
2
1),ˆ( 2
2
2
==
⎥⎥⎦
⎤
⎢⎢⎣
⎡ −−= σ
θθ
πσθθ  
The variance 2iσ is assumed to be known, obtained from each study. This leads to a finite 
mixture model 
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P is the mixture distribution of the m subpopulations, e.g. multinomial distribution, 
estimated from data by the vector of mixture weights pj.  
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with pj ≥ 0, j=1, …, m, and p1+p2+ …+ pm=1. Each pj denotes the probability of a study 
belonging to a certain subpopulation with parameter of θj. Note that the number of 
components m needs to be estimated from data as well.  
 
If we consider the component membership as missing data, we have observed data Y and 
the unknown indicator variable Z, which indicates the membership of the ith study in the 
jth component. Let zij Є {0, 1} denote the value of Zj for study yi. The complete data 
likelihood is  
L(P, θ) = ijij zji
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The complete data log likelihood is given by  
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As shown in Section 3.2.3.4, the EM algorithm can be used to estimate the distribution 
parameters (i.e. P and θ). In the E-step of the EM algorithm, zij is replaced with their 
expected values given the data y1, y2, …, yk. The M-step involves maximization of the 
current expected complete data likelihood. The CAMAN from Schlattman (2009) 
implements the EM algorithm in meta-analysis setting. Based on the likelihood statistics, 
CAMAN provides estimates for each Pj, and corresponding θj.  
 
A simulation study was conducted to evaluate the performance of the combined VEM 
and EM algorithm implemented in CAMAN for identifying the number of components in 
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meta-analysis settings. The simulation covers meta-analyses that include 30, 60, and 90 
studies, with binary outcomes from two equal sized groups (treatment: nt and control: nc). 
The underlying event rate from the control group is 0.10 compared to the event rates in 
the treatment group of 0.10, 0.20, and 0.3 (RR=1, 2, and 3, respectively). The sample 
sizes for these studies were assumed to follow the lognormal distribution with mean of 7, 
and standard deviation of 0.7.  The observed event rates from the two groups were 
arcsine transformed. Therefore, the variable of interest is the arcsine difference between 
treatment and control groups, which is assumed to follow normal distribution with 
variance of 1/4nt + 1/4nc.  Results from simulation studies are summarized in Table 3-1. 
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True underlying distribution 
Estimated number of components (in proportion) 
1 2 3 4 5 
Number of studies in meta-analysis: 30 
1 component 0.476 0.439 0.082 0.003 0 
2 components 0 0.301 0.479 0.197 0.021 
3 components 0 0 0.267 0.434 0.248 
Number of studies in meta-analysis: 60 
1 component 0.419 0.476 0.098 0.007 0 
2 components 0 0.274 0.453 0.213 0.054 
3 components 0 0 0.184 0.411 0.296 
Number of studies in meta-analysis: 90 
1 component 0.402 0.483 0.103 0.011 0 
2 components 0 0.254 0.451 0.226 0.065 
3 components 0 0 0.186 0.385 0.298 
Table 3-1 The estimated number of components from the combined VEM and EM 
algorithms for underlying 1, 2, and 3 components mixture distributions, presented as the 
proportions of times in 1,000 simulation runs. The underlying relative risks between 
treatment and control groups were 2 for 1-component; 1 and 2 for 2-components mixture; 
and 1, 2, and 3 for 3-components mixture, with equal size component.  
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As shown, the number of studies included in a meta-analysis did not seem to affect the 
performance of the algorithm for selecting the number of components. For a single 
component distribution, the method identified correctly 40.2%, 41.9%, and 47.6% for 90, 
60, and 30 studies, respectively. With similar weight, the method selected 2-components 
distribution. While for 2 or 3 components mixtures, it chooses 1 or 2 more components 
frequently in all scenarios; it is found that the extra components represent smaller 
portions of the overall, suggesting outliers may have been considered as separate 
distributions.   These results indicate this algorithm is sensitive to data realizations, and 
should be used with caution.  
3.3.2 Bayesian hierarchical model methods 
 
In meta-analysis, the process of summarizing and integrating the findings of research 
studies in a particular area can be achieved by a relatively simple hierarchical modeling. 
In the case of known heterogeneity in a meta-analysis, it might be reasonable to consider 
the collection of studies as coming from more than one subpopulation. It is natural to 
model such a problem hierarchically, with observable outcomes modeled conditionally 
on certain parameters, which themselves are given a probabilistic specification in terms 
of further parameters, known as hyper-parameters.  
 
Gelman et al. (2000) presented the framework of hierarchical modeling in meta-analyses 
for normally distributed outcomes. Let yi represent generically the point estimate of the 
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effect θi in the ith study, such as a log odds ratio, where i=1, …, K. The first stage of the 
hierarchical normal model assumes that 
),,(~| 2iiii Ny σθθ  
where 2iσ  represents the corresponding estimated variance of the measure which is 
assumed to be known without error. At the second stage of the hierarchy, an 
exchangeable normal prior distribution was assumed, with mean μ and standard deviation 
τ, which are unknown hyper-parameters, such as 
).,(~,| 2τμτμθ Ni  
Finally, a hyper-prior distribution is required for μ, assuming τ is known, 
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The choice of the hyper-prior distribution depends on analyst’s prior knowledge about the 
subject of interest. If little is known, a non-informative uniform prior distribution may be 
used. General guidance is available in many textbooks on Bayesian analysis. Inference of 
these multi-level parameters can be obtained from the joint posterior distribution 
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In a meta-analysis to determine whether statins reduce all-cause mortality in elderly 
patients with coronary heart disease (Afilalo, et al. 2008), differences in study and patient 
characteristics introduced an additional source of heterogeneity in the estimated treatment 
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effects between trials. These differences would not be adequately dealt with in a fixed-
effects meta-analysis model that uses only variability stemming from differences in 
sample sizes. Moreover, differences in length of follow-up would not be dealt with in 
a random-effects meta-analysis model. Therefore a Bayesian hierarchical model was 
employed to account for all of these between-trial variations. Nine trials showed the uses 
of statins were associated with 22% reduction in relative risk over 5 years, with 95% 
credible interval between 11% and 35%. 
 
When one suspects that the lack of homogeneity among studies in meta-analysis may be 
due to the presence of two or more distinct subpopulations, a mixture of normal 
distributions can be introduced with one additional hyper-parameter π, which is the 
mixing probability for the subpopulations. The mixture distribution can be considered as 
the mixtures of randomly samples from its components. The mixing distribution can be 
assumed to be a uniform for two components. For more than two components a 
multinomial distribution, or more formally a Dirichlet distribution, can be employed. The 
Dirichlet distribution returns a finite-dimensional set of probabilities (for some size M, 
specified by the parameters of the distribution), all of which sum to 1. This can be 
thought of as specifying a finite-dimensional discrete distribution. That is, a Dirichlet 
distribution can be thought of as a distribution over M-dimensional discrete distributions.  
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Let j=1, …, m specify the underlying mixture components, the outcome from the ith study 
follows 
).,(~| 2jijijiji Ny σθθ  
The underlying study effect in component j, given the true mean and standard deviation 
of the component has the distribution 
).,(~,| 2τμτμθ jjji N  
Assume that τ is known; the distribution of the hyper-parameters is then 
),()()|(),( jjj pppp μττμτμ ∝=  
and the mixture probability is assumed to be 
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Inference of these multi-level parameters in j components mixture model can be obtained 
from the joint posterior distribution 
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In practice, unless known otherwise, the joint posterior distribution will be considered for 
different values of m. The final determination of the number of components in a mixture 
model is based on the Bayes Factors.   
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3.4 DISCUSSION AND CONCLUSIONS 
As standard practice, meta-analysis follows a protocol that includes a detailed plan for 
conducting the literature search, and inclusion and exclusion criteria for studies. To avoid 
potential biases, the studies should include all available data relevant to the topic, 
including research papers, abstracts both published and unpublished. A comprehensive 
list of inclusion and exclusion criteria may be complex and requires careful consideration 
of many factors, such as study design, patient population, types of experimental and 
control therapies, quality of studies, study length, and data availability for the outcomes 
of interest. The process of obtaining all the information is typically carried out by two or 
more independent investigators, with pre-defined adjudication rules for any 
disagreement. The primary goal for these tasks is to ensure that data acquired from 
studies or trials represent an exhaustive collection of homogeneous research relevant to 
the topic that would allow these studies to be aggregated and an overall summary 
measure obtained to address the objectives of the investigation. However, in reality, there 
are no two studies that are the same. Researchers are required make assumptions based 
on their subject matter knowledge. As in Leucht et al. (2009) meta-analysis of second-
generation versus first-generation antipsychotic drugs for schizophrenia, publications 
from 1992 through 2005 were included with study durations from 4 to 104 weeks. These 
studies evaluated risperidone doses between 4 to 6 mg per day in children, adolescents, 
adults, and elderly patients. Disease status ranged from newly admitted, acute, to chronic, 
refractory schizophrenia. The assessment of homogeneity heavily relies on limited 
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statistical tests, such as the Q and I2 statistics. It is known that these statistical tests lack 
power largely because the number of relevant studies in meta-analysis is usually modest. 
Therefore, even in situations where statistical tests do not suggest heterogeneity, 
investigators must proceed with caution. The potential for underlying differences within 
the studies exist due to many factors. In the risperidone data mentioned above, the factors 
include, but are not limited to, the wide range of patient age groups, multiple dosages, 
varying disease status, different study durations, and the time period over which the 
studies were conducted. The random effects model has been used almost exclusively in 
dealing with extra variability at study level, but the assumption of a single underlying 
distribution (e.g. treatment effect, adverse event rate) may not be appropriate. There may 
exist fundamental differences within the studies, such as not all the studies being sampled 
from a common distribution, rather than from different underlying distributions, 
depending on certain unknown factors of the study. In biomedical research, proper 
characterization of these distributions (or subpopulations) can provide important 
information for a better understanding of treatment effect or risks associated with 
treatment, and therefore can lead to improved patient care.  
 
Mixture distribution modeling can be utilized to meet this need. With different 
distributions and number of components within, a mixture model can accommodate 
heterogeneity in the study outcomes. The parameter estimates for each component 
provide unique insight for the problem at hand. Specifically to biomedical research, there 
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are several advantages for the use of mixture modeling methodologies in handling 
heterogeneity. First, even in highly regulated controlled clinical trials conducted by 
pharmaceutical companies, a wide range of patient populations are normally included. 
For example, typically adult studies include ages 17 and over, men and women, and 
different race/ethnicity groups. Many of these patient characteristics could result in a 
difference in response to the study treatment. Secondly, global, multiregional studies are 
common, particularly in confirmatory pivotal trials for regulatory filing. There are 
concerns about the potential underlying differences due to medical practice, culture, and 
economics in different countries. Thirdly, even in randomized, double blind, adequately 
powered, and rigorously monitored clinical trials, the compliance to study treatment and 
adherence to study procedures can vary significantly. In the analysis of clinical trial data, 
an analyst heavily relies on randomization, and the Intent to Treatment (ITT) principle. 
To account for heterogeneity, adjustment for covariates is routinely carried out. However, 
pre-specified factors may not be adequate to address heterogeneity. Nevertheless, results 
from these studies are often used in meta-analysis in which these factors become even 
more divergent. By the use of multiple components, local effects can be handled formally 
thorough a latent variable identifying heterogeneity. Along with this desirable feature, 
there are non-trivial disadvantages of using mixture models. In theory, mixture modeling 
is extremely flexible, but it can get very complex for implementation, such as allowing 
mixtures of different types of distributions with unknown number of components. The 
estimation of parameters and the number of components can become a challenge under 
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both the maximum likelihood based and Bayesian based approaches.  Another issue is 
that mixture estimation is sensitive to data irregularities, as shown from simulation 
studies in meta-analysis settings - even the correct identification of the number of 
components is difficult. Lastly, mixture models can pick up outliers as separate 
components, which may not be of interest or desirable in certain situations. In meta-
analysis, these pros and cons become more pronounced due the fact that studies are 
selected based on limited knowledge, and modest numbers of suitable studies are 
obtained.   
 
We think that the finite mixture modeling can be used to assess the underlying 
assumption of a single distribution for data at hand, in particular, when there are 
indications of heterogeneity present. In meta-analysis, it is common that only limited 
study level data is available, meaning proper account for lack of homogeneity through 
covariates may not be feasible. The number of components and associated component 
parameters from FMM can provide further insight to the meta-analytic investigation.  
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4 DATA ANALYSIS APPLICATIONS 
SUMMARY 
This chapter includes analysis results of two different meta-analyses, utilizing the 
approximation methods for the arcsine transformation discussed in Chapter 2, and the 
finite mixture modeling discussed in Chapter 3. 
The four approximation methods of arcsine transformation were applied to the meta-
analysis of association between serious rare cardiovascular events and the use of a Type 2 
diabetes medicine, rosiglitazone (marketed as Avandia). These data were obtained from 
Nissan and Wolski (2010), including 56 independent randomized studies with a total of 
35,531 patients. These approximations provide a measure similar to the risk difference 
(RD) with variance always defined. Because there was no evidence of statistical 
heterogeneity among these studies, the inverse variance meta-analysis method was 
utilized to obtain overall risk estimate. Consistent with the use of the arcsine difference 
(AD), the four approximation methods (RAUD, SAUD, MRAUD, and TRAUD) showed 
statistically significant increased risk of MI in patients who received rosiglitazone 
(p<0.026). The non-linear approximation (TRAUD) yielded a risk estimate closest to RD 
and RDc, followed by the estimate from MRAUD. 
The finite mixture model method was applied to the meta-analysis of association between 
Behçet's disease (BD) and HLA-B51/B5 carriage. The BD data were obtained from 
Menthon et al. (2009), and consist of 80 independent case-control studies with a total of 
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4,800 cases and 16,289 controls. AD was chosen as a risk measure to accommodate zero 
events in two studies, and the heterogeneity measure was I2 = 68% (p < 0.001). The 
overall estimate from the random effects model was 0.404 (p < 0.001), with 95% CI of 
0.371 to 0.438. To further explore the nature of heterogeneity, finite Gaussian mixture 
models with various components were examined. The estimates from a two component 
mixture model indicate that there are two potential sub-populations in terms of the risk 
level of HLA-B51/B5 carriers developing BD. The low risk level (AD = 0.264) represents 
approximately 37.3% of the subjects, compared to high risk level (AD = 0.486) from 
about 62.7% of the population. These results indicate the heterogeneity may be due to the 
mixing of two separate sub-populations with different risk levels. 
 
4.1 THE AVANDIA DATA EXAMPLE 
4.1.1 Introduction 
Safety concerns associated with prescription drugs detected from meta-analytic findings 
have recently received a great deal of public attention.  The most significant example is 
related to Rosiglitazone maleate, a blood sugar level control drug for Type 2 diabetes, 
marketed as Avandia by GlaxoSmithKline (GSK). Approved by the US Food and Drug 
Administration (FDA) in 1999, rosiglitazone became world’s best-selling drug, reaching 
sales of $3.2 billion in 2006. The controversy arose in the summer of 2007 after Nissen 
and Wolski (2007) published their findings of significantly elevated risk for myocardial 
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infarction (MI), commonly known as a heart attack, which is an event where blood 
cannot reach part of the heart. Using fixed effect analysis, they estimated the odds ratio 
(OR) for MI to be 1.43 (95% confidence interval [CI], 1.03 to 1.98; p=0.03) for patients 
receiving rosiglitazone compared to those who did not. They also showed a borderline 
significant increased risk for cardiovascular (CV) mortality with an OR of 1.64, (95% CI, 
0.98, 2.74, p=0.06). These results were based on a meta-analysis of 42 controlled clinical 
trials, including 15,560 patients assigned to regimens including rosiglitazone, and 12,283 
assigned to a comparator regimen that did not include rosiglitazone. These trials were 
identified through a search of the published literature, the FDA website, and clinical trials 
registries. All trials needed to have duration of more than 24 weeks.  These findings were 
widely publicized and prompted a review of the drug by the FDA. While conducting its 
own analysis, the FDA issued a Safety Alert on May 21, 2007 (FDA Issues Safety Alert 
on Avandia, 2007), citing that there was a potentially significant increase in the risk of 
heart attack and heart-related death in patients taking rosiglitazone. However, other 
published and unpublished data from long-term clinical trials of rosiglitazone, including 
an interim analysis of data from the RECORD trial (a large, ongoing, randomized, open 
label trial) and unpublished re-analyses of data from DREAM (a previously conducted 
placebo-controlled, randomized trial) provided contradictory evidence about the risks of 
patients treated with rosiglitazone. On July 30, 2007 an Advisory Committee of the FDA 
concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated 
with a greater risk of myocardial ischemic events (including heart attacks) than placebo, 
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but data from several long term, prospective clinical trials showed that when 
rosiglitazone was compared to metformin, or sulfonylurea, there was no difference in the 
risk of heart attack. This data, coupled with its own meta-analysis, prompted the FDA to 
state that the data on the association between rosiglitazone and myocardial ischemia were 
inconclusive. 
 
A separate meta-analysis of long-term risk of CV events with rosiglitazone by Singh and 
colleagues was published in the Journal of the American Medical Association in 
September, 2007.  Singh et al. (2007) used fixed-effects meta-analysis of 4 randomized 
controlled trials including 14,291 patients. They found that rosiglitazone significantly 
increased the risk of myocardial infarction with a relative risk (RR) of 1.42 (95% CI, 1.06 
-1.91; p=0.02), as well as heart failure (RR = 2.09, 95% CI, 1.52-2.88, p<0.001).    
 
Since then, publications have raised questions about the method used in Nissen and 
Wolski (2007) meta-analysis. Diamond et al. (2007) pointed out that the analysis was not 
based on a comprehensive search for all studies that might yield evidence about 
rosiglitazone’s cardiovascular effects. And the studies were combined using fixed effect 
analysis on the basis of a lack of statistical heterogeneity, despite substantial variability in 
study design and outcome assessment. Rucker and Schumacher (2008) linked the meta-
data to the Simpson’s paradox, and showed that the MI rate was the lower, for greater 
proportions of patients in the rosiglitazone group. They claimed that there is no effect of 
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the treatment, but that the Nissen and Wolsky finding of an effect was an artifact of the 
studies included in the meta-analysis, and noted that this kind of heterogeneity in study 
design cannot be detected through statistical heterogeneity measures, such as τ2, H or I2.  
Bracken (2007) questioned the use of the Peto’s OR as there is a substantial imbalance in 
the number of patients between the treatment groups. Diamond and Kaul (2007) 
examined the impact of the exclusion of 4 trials from the MI analysis, and 19 trials from 
the mortality analysis, in which there were no events in either arm by Nissen and Wolski 
(2007). Using Bayesian meta-analysis methods with the use of a standard continuity 
correction accounting for values of zero, they found no statistically significant elevation 
in risk for either MI or death. In January 2010, the Senate Committee on Finance released 
a Staff report on GlaxoSmithKine and the diabetes drug Avandia (2010). The report was 
critical of both GlaxoSmithKline’s internal procedures, and of the FDA’s procedures on 
adjudicating drug safety issues. The New York Times (2010) and other news outlets 
published articles on the controversy.  
 
In response, Nissen and Wolski (2010) published an updated meta-analysis of the risk for 
MI and CV mortality, addressing concerns previously raised. An additional 14 new 
clinical trials were added to the 42 clinical trials included in the 2007 publication through 
a new search. Further details about the updated paper are provided in Section 4.1.2. They 
re-affirmed rosiglitazone therapy significantly increased the risk of MI (OR, 1.28; 95% 
CI, 1.01-1.62; p=0.04), but not CV mortality (OR 0.99; 95% CI, 075-1.32; p=0.96). In 
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response to data that suggest an elevated risk of cardiovascular events, such as heart 
attack and stroke, in patients treated with Avandia, the FDA, on September 23, 2010, 
announced that it would significantly restrict the use of Avandia (rosiglitazone). 
Following this announcement, Avandia is now only for use in patients with Type 2 
diabetes who cannot control their diabetes on other medications.  
 
Since both MI and CV mortality were rare events in these trials, as noted in the 
publications, commonly used meta-analysis methods face challenges in the analysis of 
these events. The arcsine transformation and use of arcsine difference as effect measure 
provide a valid alternative in such situations. Furthermore, the approximation methods 
proposed convert the arcsine unit to an intuitive percent like measure of treatment effect, 
such that they can be interpreted and understood easily. In the following sections, in an 
effort to show the utility, these methods will be applied in the re-analysis of data included 
in Nissen and Wolski (2010) publication. 
 
4.1.2 The rosiglitazone dataset and analysis in original publication 
In Nissen and Wolski (2010), as shown in Figure 4-1, studies were carefully evaluated, 
and 56 randomized controlled trials of rosiglitazone at least 24 weeks in duration that 
reported cardiovascular adverse events were selected. The statistical assessment of 
heterogeneity across the 56 trials did not show evidence of lack of homogeneity for both 
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comparison, the highest trial percent of MI was 2.7% in subjects receiving comparator 
drugs, with 35 trials without any MI cases. For CV mortality, the highest trial rate was 
4.5% in subjects received rosiglitazone, with 33 trials with zero events, and the highest 
rate in subjects who did not receive rosiglitazone was 3.5%, with 44 trials having no 
events.  
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does not include trials with zero cases in both rosiglitazone and comparator groups in 
calculation. This has raised concerns about the validity and robustness of the results. In 
next section, alternative measures discussed in Chapter 2 will be presented and used in 
the re-analysis. The entire dataset including the RECORD trial data will be used. 
Therefore the results from this re-analysis should be considered specifically as analysis 
including the RECORD trial. Similarly, we focus on the analysis of MI events from the 
studies. Results for CV mortality can be obtained in similar manner.  
 
4.1.3 Arcsine transformation and approximation methods 
 
As discussed in detail in Chapter 2, the arcsine transformation along with its 
approximation methods provide alternative measures that can accommodate trials with 
zero events in both arms.  This is an advantage for this method above most alternative 
methods when considered for use with rare safety events data. 
4.1.3.1 Arcsine Difference (AD) as risk measure 
The arcsine transformation of the reported MI event proportion was performed for each 
treatment group within a trial, and the AD between rosiglitazone and its comparator was 
calculated for each trial, as such 
ADi = Sin-1 tip  - Sin
-1
cip , 
where pti and pci represent the proportions of MI cases for the rosiglitazone and 
comparator groups in the ith study. To evaluate the homogeneity assumption, Figure 4-3 
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shows a funnel plot of ADs against their standard errors for MI events in the 56 studies. 
Consistent with OR estimates obtained by Nissen and Wolski (2010), there was no 
appreciable heterogeneity among these trials shown in the plot (I2 = 0, p = 0.579). Notice 
that only one study falls outside of the funnel determined by confidence interval width 
around the combined estimate for each value of the standard error (Y-axis). Note the 
vertical band of studies above the horizontal position for AD of 0 - these are due to 
studies with zero events. 
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Figure 4-3 Funnel plot of ADs for MI events, each dot indicates a study of the 56 trials 
included. 
 
 
Furthermore, the AD estimates along with 95% CI for MI events for the 56 studies are 
provided in Figure 4-4 (studies 1 to 35) and continued in Figure 4-5 (studies 36 to 56). 
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Figure 4-4 Forest plot of ADs for MI events for first 35 studies included. The size of the 
square around the AD estimate is the study weight (the inverse of standard error squared). 
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Figure 4-5 Forest plot of ADs for MI events for studies 36 - 56. The size of the square 
around the AD estimate is study weight (the inverse of standard error squared). 
As shown, the ADs range from -0.15 (95% CI: -0.35, 0.06; Study 100684) to 0.16 (95% 
CI: -0.06, 0.38; Study 49653/128). Negative AD values indicate higher risk of MI in the 
comparator group, while positive AD values show higher risk in the rosiglitazone treated 
group. For trials with zero MI cases in both groups, the AD equals zero with a standard 
error depending on the study sample size. Among the 56 trials, 29 studies had non-
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statistically significant positive AD estimates, including the 3 largest studies (DREAM 
trial, ADOPT, and RECORD trial); 12 studies had negative AD estimates, but only Study 
49653/134 showed a statistically significant lower risk of MI in patients receiving 
rosiglitazone (AD = -0.09; 95% CI: -0.16, -0.01). The remaining 15 studies had AD of 
zero. 
 
4.1.3.2 Stevens arcsine unit difference (SAUD) as risk measure 
One of the two existing linear approximations of the arcsine transformation, the Stevens 
arcsine unit (SAU) was calculated for MI in rosiglitazone group for the ith study as 
SAUti = 50 – 1000 Sin-1(1 – 2pti), 
where pti is the MI rate in rosiglitazone group. The SAU of MI for the comparators group 
(SAUci) is calculated similarly with pci instead of pti. And the SAUD between 
rosiglitazone and its comparators is then  
SAUDi = SAUti – SAUci. 
The SAUDs along with 95% CIs are shown in Figures 4-6 and continued in 4-7. Similar 
to AD risk measure, the lowest SAUD is -9.26 (95% CI: -22.34, 3.82) from Study 
100684, while the highest SAUD is 10.17 (95% CI: -3.96, 24.30) from Study 49653/128. 
The numbers of studies with positive (i.e. = 29), null (i.e. = 15), and negative (i.e. = 12) 
values of SAUDs were consistent with these based on AD.  Again Study 49653/134 
showed statistically significant lower MI risk in patients receiving rosiglitazone (SAUD = 
-5.39; 95% CI: -9.95, -0.83). 
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Figure 4-6 Forest plot of SAUDs for MI events for first 35 studies included. The size of 
the square around the SAUD estimate is study weight (the inverse of standard error 
squared). 
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Figure 4-7 Forest plot of SAUDs for MI events for the studies 36 - 56. The size of the 
square around the SAUD estimate is study weight (the inverse of standard error squared). 
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4.1.3.3 Rationalized arcsine unit difference (RAUD) as risk measure 
As a further effort to convert the AD into more intuitive percentage-like measure, RAUD 
approximation was carried out. First, the RAU for MI in rosiglitazone group for the ith 
study was calculated as 
RAUti=1.46(31.83098861*T-50)+50,  
where T=2* Sin-1 tip , and pti is the MI proportion in rosiglitazone group.  
 
The RAU of MI for the comparators group (RAUci) can be calculated similarly with pci 
used instead of pti. And the RAUD between rosiglitazone and comparators is then 
RAUDi = RAUti – RAUci. 
The RAUDs along with 95% CIs are shown in Figures 4-8 (studies 1 to 35) and 
continued in 4-9 (studies 36 to 56). As shown, the RAUDs range from -13.61 (95% CI: -
32.83, 5.62; Study 100864) to 14.95 (95% CI: -5.81, 35.71; Study 49653/128). The same 
as AD and SAUD, for trials with zero MI cases, RAUD equals zero with standard error 
depending on the study sample size. Because RAUD is a linear transformation of the AD, 
the numbers of studies with positive, null, and negative values of RAUDs were consistent 
with these based on AD. Again, Study 49653/134 showed statistically significant lower 
MI risk in patients who received rosiglitazone (RAUD = -7.92; 95% CI: -14.62, -1.22). 
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Figure 4-8 Forest plot of RAUDs for MI events for first 35 studies. The size of the square 
around the RAUD estimate is study weight (the inverse of standard error squared).  
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Figure 4-9 Forest plot of RAUDs for MI events for the rest of studies included. The size 
of the square around the RAUD estimate is study weight (the inverse of standard error 
squared). 
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4.1.3.4 Modified rationalized arcsine unit difference (MRAUD) as risk 
measure 
MRAU was proposed to correct proportions near 0 and 1 where RAU deviates 
significantly from the percentage values. It was shown to provide closer approximation to 
percent than RAU for proportions above 0.85 or below 0.15. The MRAU of MI in 
rosiglitazone group of the ith study is calculated as 
If pti ≤ 0.15, MRAUti=0.0393+0.4382* Sin-1 tip ;  or 
If pti >0.15 but < 0.85, MRAUti=RAUti; or  
If pti ≥ 0.85, MRAUti= 0.5463+0.3143* Sin-1 tip , 
where pti is the MI rate in rosiglitazone group.  
MRAU of MI for the comparators group (MRAUci) can be obtained similarly. And 
MRAUD for the ith study is 
MRAUDi = MRAUti – MRAUci, 
The MRAUDs along with 95% CIs are shown in Figures 4-10 (studies 1 to 35), and 4-11 
(studies 36 to 56). The MRAUDs follows the same pattern as previous three risk 
measures, ranging from -6.41 (95% CI: -15.48, 2.65, Study 100684) to 7.05 (95% CI: -
2.74, 16.84; Study 49653/128). Estimate for Study 49653/134 is -3.73 (95% CI: -6.89, -
0.58), indicating statistically significant lower risk in patients who received rosiglitazone. 
The 95% CI of estimates from all other studies include zero. Note that the MRAUD 
values tend to be closer to 0 than the RAUD values. 
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Figure 4-10 Forest plot of MRAUDs for MI events for first 35 studies included. The size 
of the square around the MRAUD estimate is study weight (the inverse of standard error 
squared). 
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Figure 4-11 Forest plot of MRAUDs for MI events for studies 36 to 56. The size of the 
square around the MRAUD estimate is study weight (the inverse of standard error 
squared). 
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4.1.3.5 Taylor series approximation of arcsine unit difference (TRAUD) 
as risk measure 
We further used the non-linear approximation method proposed in Chapter 2, TRAU. For 
TRAU of MI in rosiglitazone group of the ith study: 
TRAUti = [ 2
5131
1 ]
120
)(
6
)( titi
ti
pSinpSin
pSin
−−
− +− , 
where pti is the MI proportion in rosiglitazone group.  
TRAU of MI for the comparators group (TRAUci) can be obtained similarly with pci 
instead of pti. And TRAUD for the ith study is 
TRAUDi = TRAUti – TRAUci, 
The variance was derived based on the parametric bootstrap method obtained from 1,000 
random samples. The TRAUDs along with 95% CIs are shown in Figures 4-12 (studies 1 
to 35), and continued in 4-13 (studies 36 to 56). As expected, TRAUDs had much 
narrower range from -2.13 (95% CI: -6.40, 2.15, Study 100684) to 2.79 (95% CI: -1.85, 
7.43, Study 49653/211), reflecting its close approximations to observed event 
percentages. Note than while TRAUD for Study 59653/134 remains negative (-0.72, 95% 
CI: -1.8, 0.35), it is no longer statistically significant. It should be noted that, the 
parametric bootstrap variance was based on observed MI even proportions. When the 
observed proportion equals to zero, a small constant (0.0001) was added. Because of the 
extreme low values, the variance estimate for TRAUDs was smaller than the three linear 
approximation methods. This resulted in tighter 95% CIs as shown on the Forest plots.   
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Figure 4-12 Forest plot of TRAUDs for MI events for first 35 studies included. The size 
of the square around the TRAUD estimate is study weight (the inverse of standard error 
squared). 
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Figure 4-13 Forest plot of TRAUDs for MI events for studies 36 - 56. The size of the 
square around the TRAUD estimate is study weight (the inverse of standard error 
squared). 
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4.1.4 Results and conclusions 
As summaries of the newly proposed risk measures, descriptive statistics based on MI 
rates observed in the 56 trial data are provided in Table 4-2. As noted earlier, the TRAUD 
has the best approximation to RD, followed by, in order, MRAUD, SAUD, and RAUD.   
Risk measure (in %) Mean (SD1) Median (IQR2) 
RD 0.177 (0.783) 0.015 (0, 0.403) 
RAUD 1.646 (5.420) 0.098 (0, 5.616) 
SAUD 1.120 (3.688) 0.067 (0, 3.822) 
MRAUD 0.776 (2.555) 0.046 (0, 2.648) 
TRAUD 0.177 (0.783) 0.015 (0, 0.403) 
1SD = Standard Deviation; 2IQR = Inter Quartile Range; 
Table 4-2 Descriptive statistics of risk measures for MI based on the rosiglitazone 
dataset. 
 
As argued in Nissen and Wolski (2010), there is little evidence of heterogeneity among 
the studies included. The fixed effect, inverse variance method was utilized in deriving 
overall risk differences between rosiglitazone groups and comparators, along with 95% 
CIs. For illustrational purposes, the risk measure, AD, was multiplied by 100 to obtain 
similar scale. In order to provide comparable risk measures, RD and RD with continuity 
correction (i.e. 0.5) were calculated additionally. Because the variance for RD is zero 
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when there are zero events in rosiglitazone and comparators groups, the overall RD was 
calculated based on non-zero events studies only. Therefore, RD results should be viewed 
as illustrations rather than a valid risk measure. For completeness, analysis of CV 
mortality was conducted and summarized along with the analysis MI events (Table 4-3). 
  
Risk 
 Measure 
MI CV Mortality 
Estimate 95% CI p-value Estimate 95% CI p-value
RD 0.17 -0.09,  0.42 0.203 -0.001 -0.19,  0.42 0.990 
RDc1 0.14 -0.002,  0.28 0.054 0.05 -0.06,  0.28 0.397 
AD 1.63 0.55, 2.71 0.003 0.804 -0.28, 1.89 0.145 
RAUD 1.51 0.51, 2.52 0.003 0.748 -0.26, 1.75 0.145 
SAUD 1.03 0.34, 1.71 0.003 0.51 -0.18, 1.19 0.145 
MRAUD 0.71 0.24, 1.19 0.003 0.35 -0.12, 0.83 0.145 
TRAUD 0.13 0.02,  0.25 0.026 0.05 -0.05,  0.14 0.314 
1: RDc = RD with continuity correction 
Table 4-3 Overall risk estimates, 95% CI, and p-values from re-analyses of rosiglitazone 
data. 
 
For the risk of MI, all measures showed consistent increased risk in patients who received 
rosiglitazone compared to those who did not, with a range of 0.13% (TRAUD) to 1.63% 
(AD). The risks measured by AD, its linear approximations, and TRAUD were 
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statistically significant (p <0.026). In contrast, there was no statistical significance in RD, 
or RDc (p > 0.05). As expected, the TRAUD estimate was the closest to both the RD and 
RDc among the approximation methods, and the MRAUD estimate was closer to the RD 
than either the RAUD or SAUD. 
 
For the risk of CV mortality, except for the RD, all measures showed slightly elevated 
risk in subjects who received rosiglitazone compared to those who did not. However, the 
risk was small by all measures (< 1%), and not statistically significant, indicating the 
finding was inconclusive. 
 
It is worth noting that the rosiglitazone data represents extremely rare and severe safety 
outcomes. Even with the large numbers of studies and sample sizes, it is challenging for 
conventional meta-analysis methods. Nevertheless, the AD risk measure demonstrated 
higher statistical precision compared to the RD and RDc in this rare events situation.  The 
approximation methods of the AD preserved the precision, and provided more 
meaningful measures that were similar to percentages. Among them, TRAUD estimate 
yields the closest estimate to the RD.   
 
In conclusion, the linear and non-linear approximation methods of the arcsine difference 
provide alternative risk measures that are intuitive and much closer to percentages. The 
newly proposed MRAUD and TRAUD showed closer approximations to the RD, than the 
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previously-established RAUD and SAUD. The simple computations for these 
approximations make them alternatives in situations where more intuitive measures than 
the AD are desired, and these measures are especially applicable in datasets with modest 
to rare events.      
 
4.2 THE BEHÇET'S DISEASE DATA EXAMPLE 
In this section, the finite mixture model methods discussed in Chapter 3 are utilized to 
deal with heterogeneity in a meta-analysis, and compared to the fixed effect and random 
effects models.  
4.2.1 Introduction 
Behçet's disease (BD) is a chronic vasculitis of arteries and veins of all sizes 
characterized by recurrent oral ulcers, genital ulcers, ocular and skin involvement, and 
other multi-systemic features. Despite a worldwide distribution, BD clusters in an area 
that extends from far eastern Asia to the Mediterranean basin.  To investigate whether or 
not host genetic factors play a pivotal role in determining susceptibility to BD, Menthon 
et al. (2009) evaluated the risk increase for BD development associated with HLA-
B51/B5 carriage and identified clinical or methodological factors potentially affecting the 
effect size of this genetic association. 
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4.2.2 The BD dataset and analysis in original publication 
Menthon et al. (2009) carefully selected 80 case–control study populations with sufficient 
information to construct a 2×2 contingency table for the frequencies of HLA-B51/B5 
genotypes in BD cases and controls. These studies were identified by electronic searches 
of the PubMed MEDLINE database between January 1, 1973 and December 31, 2007. 
Figure 4-14 shows the flow diagram of study selection process and results. Study level 
data, OR estimate, as well as overall estimates of the OR and heterogeneity measures are 
provided in Table 4-4. 
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Figure 4-14 Flow diagram showing the numbers of studies included and excluded from 
the analysis and the reasons for exclusion. Source: Menthon et al. (2009). 
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Table 4-4 Individual study level data and overall estimates. Source: Menthon et al. (2009)  
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The final dataset included a total of 4,800 cases and 16,289 control subjects. The OR for 
HLA-B51/B5 carriers to develop BD across the primary datasets were all >1 with values 
ranging from 1.18 to 34.62. For 2 studies with no controls having positive findings for 
HLA-B51/B5, a single positive control was added to allow OR and CI computations. For 
the overall estimate (I2 = 60%) and within most of the subgroups, analyses showed 
moderate heterogeneity (I2 = 38–78%). Random-effects logistic models were used to 
calculate pooled estimates for the frequency of the HLA-B51/B5 allele in BD cases and 
control populations. The pooled OR for BD susceptibility was estimated to be 5.78 (95% 
CI: 5.00–6.67).  
4.2.3 Use of mixture models 
As noted in Menthon et al. (2009), there were 2 studies with no controls having positive 
findings for HLA-B51/B5, and in these studies, a single positive control was added to 
allow OR and CI computations. Since this could cause bias toward no association, the 
arcsine difference of cases and controls carrying the HLA-B51/B5 allele were calculated 
and used as effect measure in my re-analysis. In these 80 datasets, the ADs were all 
positive, ranging from 0.026 to 0.821. The distribution of the ADs is shown in Figure 4-
15, suggesting some level of departure from a normal distribution. 
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Figure 4-15 Histogram of ADs obtained from 80 independent datasets 
  
Consistent with the OR analysis, the heterogeneity measure of the ADs is (I2 = 68%, 
p<0.001), indicating the fixed effect model may not be justified. In Figure 4-16, about 
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25% of the data points representing studies fall outside of the funnel that should enclose 
95% of studies under a fixed effect, and the points are roughly equally distributed on both 
sides which does not indicate bias. A random effects model analysis was carried out, and 
the overall AD was estimated to be 0.404 (p < 0.001), with 95% CI of 0.371, 0.438. This 
result indicates a statistically significant positive association between HLA-B51/B5 allele 
carriage and BD. 
  
Figure 4-16 Funnel plot of AD vs. standard error for HLA-B51 in 80 datasets. Note that 
22 studies fall outside the boundaries. 
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To further explore the nature of heterogeneity among the studies, finite mixture model 
methods were implemented.  As the first step, non-parametric bootstrapping methods 
were used to provide an estimate of the underlying number of components. Based on 
1,000 replications, the mode of the bootstrap samples was a three component Gaussian 
mixture model. With the EM algorithm, the component means and mixing probabilities 
were obtained and provided in Table 4-5. The mixture model suggested roughly three 
equally spaced centers, 0.205, 0.366, and 0.509, with mixing probabilities of 0.201, 
0.315, and 0.484, respectively.  
Component Mean Mixing probability 
Component 1 0.206 0.201 
Component 2 0.366 0.315 
Component 3 0.509 0.484 
Table 4-5 Component means, and mixing probabilities from a three components Gaussian 
mixture applied to the BD dataset. 
 
It should be pointed out that based on the simulation study results in Chapter 3, the 
bootstrapping methods tends to over-estimate the number of components in a mixture 
distribution. In addition, when the component means are close to each other, the 
difference in means is of little practical meaning. One may choose to have a more 
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parsimonious model instead (i.e. fewer components). Therefore, AIC and BIC statistics 
were obtained from mixture models with different numbers of components along with the 
fixed effect and random effects models, shown in Table 4-6. These results indicate that 
the random effects model provides the best fit of the data. The AIC statistic suggests the 
next best fit is a three component mixture model, while the BIC statistic points to a two 
component Gaussian mixture model. The differences in AIC and BIC between a 2-
component and 3-component mixture models were minimal; suggesting a mixture of two 
components may be a reasonable choice for practical purposes.  
Model AIC BIC 
Fixed effect 13.6 16.0 
Random effects -61.6 -56.8 
Mixture - 1 component 13.6 16.0 
Mixture - 2 components -57.4 -50.2 
Mixture - 3 components -60.6 -48.7 
Mixture - 4 components -56.6 -40.0 
Mixture - 5 components -52.6 -31.2 
Table 4-6 AIC and BIC statistics from fixed effect, random effects, and 1 thorough 5 
components mixture models. 
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Therefore, a two component Gaussian mixture model was fit to the data, and the 
estimates are shown in Table 4-7. The results suggest that a minority of the studies 
(37.3%) showed a weaker (AD=0.264) association between the carriage of the HIA-
B51/B5 allele and BD, compared to 0.486 from the rest (62.7%). The risk is almost 
doubled in the second component, indicating there were potentially two sub-populations 
within the 80 studies included in the original meta-analysis.  Figure 4-17 shows two 
funnel plots of means from two components, indicating that the fit of the two-component 
mixture appears plausible.  
Component Mean 95% CI P for Component 
Component 1 0.264 0.195,  0.333 0.373 
Component 2 0.486 0.428,  0.543 0.627 
Table 4-7 Component mean, 95% CI, and proportion for a two component Gaussian 
mixture  
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Figure 4-17 Funnel plots of effect size (AD) vs. standard error in two component mixture 
model.  
 
For illustrational purposes, Bayesian hierarchical model methods were applied to two 
component Gaussian mixture model shown above.  We can write a two-component 
Gaussian mixture model for BD data with density as follows: 
 
for studies i = 1, …, 80. 
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There are four parameters in the density: µ1, µ2, and p, representing the two 
component means, common variance within each component, and mixing probability 
with 0 ≤ p ≤ 1. Suppose the following prior distributions are placed on the four 
parameters: 
π(p) = uniform(0, 1), 
π(µ1), π(µ2) = N(0, 1e6), and 
π(  = IG (shape = 3/10, and scale = 10/3). 
where π(.) indicates a prior distribution and IG is the density function of the inverse-
gamma distribution. Priors of this type are often called diffuse priors. The uniform (0, 1) 
prior expresses the lack of knowledge about the mixture proportion. It should be noted 
that choice of these less informative priors was due to the lack of knowledge about 
underlying distributions. When one has knowledge about the matter under investigation, 
more informative priors can be used. Using Bayes’ theorem, the likelihood function and 
prior distributions determine the posterior distribution of µ1, µ2, and p as follows:  
 π(µ1) π(µ2) π(  
The SAS PROC MCMC procedure (version 9.3, 2011) obtains samples from the desired 
posterior distribution, which is determined by the prior and likelihood specified. It does 
not require the form of the posterior distribution be specified. Results from posterior 
distribution are summarized in Table 4-8 and model fit statistics are provided in Table 4-
9. 
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Parameter 
 
Mean 
Standard 
Deviation 
95% posterior intervals 
Equal Tail HPD1 
µ1 (component 1) 0.315 0.101 0.095, 0.490 0.099, 0.490 
µ2 (component 2) 0.497 0.105 0.327, 0.776 0.309, 0.716 
p for component 1 0.467 0.299 0.015, 0.975 0.014, 0.973 
 0.156 0.020 0.110, 0.191 0.114, 0.193 
1HPD = Highest posterior density  
Table 4-8 Parameter estimates from posterior distribution derived from hierarchical 
model. 
 
Deviance Information Criteria Value 
Dbar (posterior mean of deviance) -57.809 
Dmean (deviance evaluated at posterior mean) -60.077 
pD (effective number of parameters) 2.268 
DIC (smaller is better) -55.541 
Table 4-9 Deviance information criteria from posterior distribution. 
 
The results from Bayesian hierarchical modeling employed here are generally consistent 
with those obtained from likelihood based methods. The first component has a lower risk 
mean of 0.315, representing 46.7% of the total population, while mean from the second 
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component is 0.497, with 53.3% of the total population. The deviance information criteria 
(DIC) were similar to the BIC measure, suggesting that the model appears to be 
reasonable. 
4.2.4 Results and conclusions 
While all the ORs were greater than 0, there was considerable variability in risk measure 
among the 80 datasets included in the meta-analysis, with ORs ranging from 1.18 to 
34.62. Menthon et al. (2009) utilized random-effects models for the calculations of risk 
estimates. Although random-effects models generate confidence intervals with wider 
boundaries, the lower 95% confidence limits still largely supported positive odds of BD 
susceptibility for HLA-B51/B5 carriers compared to non-carriers. Therefore, it was 
argued that the underlying heterogeneity should not have major repercussions on the 
interpretation of the overall findings of the meta-analysis, but this highlights the potential 
influence of modifiers on the BD–HLA-B51/B5 association. To explore the sources of 
heterogeneity, the authors performed meta-regression analyses and identified the 
differing distribution of male gender as a significant source of between-study 
heterogeneity, although this result has to be interpreted keeping the possibility of 
spurious statistical significance in mind due to testing of multiple hypotheses in the meta-
regression. 
The results of this meta-analysis of 4,800 cases and 16,289 controls indicate that the risk 
(“AD”) of HLA-B51/B5 carriers developing BD is increased. The estimates from a two 
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component Gaussian mixture model indicate that there are two potential subpopulations 
in term of the risk level of HLA-B51/B5 carriers developing BD. The low risk level (AD 
= 0.264) represents approximately 37.3%, compared to high risk level (AD = 0.486) from 
62.7% of the total population. A Bayesian hierarchical two component Gaussian mixture 
model yielded largely consistent estimates. The means of both the low and high risk 
subpopulations shifted slightly higher to 0.315 and 0.497, respectively, with mixing 
probability for the low risk group of 46.7%. These results indicate that the heterogeneity 
among studies may be caused by the mixture of two different risk populations 
represented by different studies.  
The non-parametric bootstrapping method and AIC statistic indicated a three component 
Gaussian mixture model may be more appropriate. Estimates from a three component 
Gaussian mixture model showed 0.206, 0.366, and 0.509 for components 1 thorough 3, 
respectively, with mixing probabilities of 0.201, 0.315, and 0.484, respectively. The first 
two components appear to be largely a split of the first component in a two component 
mixture model. It should be noted that extreme values or outliers in a dataset can cause 
over-estimation of model components, in particular, when the dataset is small. There is a 
tradeoff between increasing the number of components for better fit statistics of the data 
and obtaining a most parsimonious model that fits the data adequately. While interesting, 
separating closely clustered components may be of little practical importance. The choice 
of number of components should be based on both statistical considerations and the 
subject nature under investigation. 
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There are important limitations of the applications of finite mixture modeling in meta-
analysis. First, most meta-analyses include a modest number of independent studies, 
which makes the determination of number of components difficult. While small samples 
are a problem for almost all meta-analysis statistical methods, it is particularly relevant to 
the finite mixture model, which essentially separates the overall population into sub-
populations for inference. Secondly, due to the lack of patient level covariates, the 
prediction of component membership for individual patients is more challenging. The 
estimates of the component means indicate different responses (or risk levels), but 
knowing which component an individual patient may belong to is not possible.  
In conclusion, finite mixture model methods provide an alternative for dealing with 
heterogeneity in meta-analysis.  At the least, it is worthy of consideration as a sensitivity 
analysis when the number of studies is not too small. The number of components 
suggests potential sub-populations within the overall population, and the estimates of 
component means indicate corresponding measures of each sub-population. This 
information can shed a unique light into the nature of hypothesis under investigation. In 
biomedical research, the inference from these sub-populations may provide a more 
appropriate guide for patient care and evaluation of risk.  
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5 OVERALL SUMMARY 
 
In this dissertation, we performed research in two areas of meta-analysis methodology. 
First, novel approximation methods of arcsine transformation for binary outcome data 
were proposed and studied for use as risk difference measures, particularly, for the 
analysis of rare safety events. In Chapter 2, following the introduction of two existing 
approximation methods of arcsine transformation, we developed two new, improved 
methods. These methods were evaluated extensively under various meta-analysis 
settings. Second, current mixture model methods were utilized to address one of the most 
difficult problems in meta-analysis: heterogeneity. In Chapter 3, we discussed 
heterogeneity in meta-analysis, current methods, and the use of mixture modeling to 
address the problem. In Chapter 4, the methods proposed in Chapters 2 and 3 were 
applied to real data meta-analyses. The approximation methods were applied to the 
analysis of association between serious cardiovascular diseases and the use of a 
prescription drug. The mixture models were applied to explore apparent heterogeneity 
among studies in meta-analysis of association between genetic factors and the 
development of Behçet’s disease. This chapter provides discussion on the strengths and 
the limitations of the two frameworks in meta-analysis, as well as directions for future 
research. 
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5.1 APPROXIMATION METHODS OF ARCSINE 
The use of the arcsine difference has been shown to have better statistical properties than 
commonly used OR or RR for analysis of  binary endpoint data, particularly for events 
occurring to a small proportion of subjects (Rucker et al. 2009). However, the utility of 
the AD has been limited mostly due to apparent difficulties with interpretability of the 
measure. Two existing linear approximation methods (RAUD, and SAUD), one 
improved linear approximation (MRAUD), and a newly developed non-linear 
approximation method (TRAUD) were proposed to convert arcsine units into more 
intuitive percent-like measures. After conversion, these measures become comparable to 
the RD. The variance estimates for the linear approximation methods can be easily 
obtained from the variance of AD, while the variance estimate for TRAUD requires 
parametric bootstrapping. Based on results from extensive simulation studies, the newly 
proposed MRAUD, and TRAUD showed closer approximations to the RD than the two 
existing approximation methods. In addition, the TRAUD performed best in terms of 
relative bias and coverage.  
These methods were applied to the re-analysis of a published meta-analysis that evaluated 
the association between the use of rosiglitazone (a type II diabetes treatment drug) and 
the emergence of serious cardiovascular diseases. All approximations produced similar 
statistical precision as the use of AD, while the TRAUD provided a risk measure that was 
very close to RD (or RDc), followed by MRAUD. These results indicate the 
approximation methods, in particular the TRAUD and MRAUD, may be considered as 
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alternative measures when dealing with low event proportion data, and a more intuitive 
measure is desired.   
 
5.2 MIXTURE MODELING AS SENSITIVITY ANALYSIS WHEN 
HETEROGENEITY PRESENT 
Heterogeneity among study results is a fundamental concern in meta-analysis, and how to 
best deal with it is the source of much debate. Commonly, rather than seeking to explain 
or adjust for variation between studies, random effects models are used to account for 
variation in the effect size between studies. However, the random effects model assumes 
a common underlying normal distribution for study results. In contrast, mixture model 
methods treat study results in meta-analysis as a finite mixture of unknown component 
distributions. While there are difficulties in determining the number of components, 
mixture modeling provides an appealing alternative for exploring the nature of 
heterogeneity. Estimates of component parameters and mixing probabilities show 
different risk levels, and corresponding proportions within the study population. Such 
information may reveal fundamental differences in patient populations included in a 
meta-analysis that otherwise may be masked by a single overall result.   
In application to a real meta-analysis with known heterogeneity, results from mixture 
modeling revealed that instead of a single overall risk of HLA-B51 allele carriage for 
176 
 
 
 
developing BD, there might be two separate risk levels, with approximately a third of the 
population in the lower risk group.  
 
5.3 CONCLUDING REMARKS 
With the advancement in information technology, data synthesis across different studies 
has grown rapidly in the hope of obtaining more precise estimates of the true effect size, 
as opposed to a less precise effect size estimates derived in a single study under a given 
single set of assumptions and conditions. Particularly, meta-analysis has been utilized 
extensively in the analysis of safety events in biomedical research, such as risk associated 
with use of certain medications. When safety events are uncommon, the analysis of such 
events can be difficult with typical risk measures. The use of AD was shown to perform 
well in these situations. Two newly proposed approximations of AD: MRAUD and 
TRAUD may be considered as alternative measures with more intuitive interpretation.  
  
When there is evidence of heterogeneity, in addition to random effects analysis, mixture 
modeling methods provide a framework to explore whether or not more than one 
underlying distribution is appropriate to fit the data. While there are difficulties knowing 
the exact number of components in the mixture, the analysis may be considered as a 
sensitivity analysis that probes different aspects of heterogeneity. The mixture component 
estimates and mixing probabilities can reveal sub-populations within a meta-analysis. 
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There are several important areas for further research in utilizing mixture modeling in 
meta-analysis, such as linking study-level (or patient-level if available) data to mixture 
components that would provide more concrete information that can be used for better 
patient care.   
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